<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        24-102-22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZYVOX 2 MG/ML SOLUTION FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LINEZOLID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bag
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1601.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="FRESENIUS KABI" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            FRESENIUS KABI
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER INC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XX08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zyvox is an antibiotic of the oxazolidinones group that works by stopping the growth of certain bacteria (germs) that cause infections. It<strong> </strong>is used to treat pneumonia, some infections in the skin or under the skin and some Vancomycin resistant infections. Your doctor will have decided if Zyvox is suitable to treat your infection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Zyvox</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to linezolid or any of the other ingredients of this medicine (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking or have taken within the last 2 weeks any medicines known as monoamine oxidase inhibitors (MAOIs: for example phenelzine, isocarboxazid, selegiline, moclobemide). These medications may be used to treat depression or Parkinson&rsquo;s disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;if you are breast-feeding. This is because Zyvox passes into breast milk and could affect the baby.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, pharmacist or nurse before taking Zyvox.</p><p>&nbsp;</p><p>Zyvox<strong> </strong>may not be suitable for you if you answer <strong>yes</strong> to any of the following questions. In this case tell your doctor as he/she will need to check your general health and your blood pressure before and during your treatment or may decide that another treatment is better for you.</p><p>&nbsp;</p><p>Ask your doctor if you are not sure whether these categories apply to you.</p><p>&middot; &nbsp;&nbsp;&nbsp; Do you have high blood pressure, whether or not you are taking medicines for this?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have you been diagnosed with an overactive thyroid?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you have a tumour of the adrenal glands (phaeochromocytoma) or carcinoid syndrome (caused by tumours of the hormone system with symptoms of diarrhoea, flushing of the skin, wheezing)?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you suffer from manic depression, schizoaffective disorder, mental confusion or other mental problems?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you have a history of hyponatraemia (low blood sodium levels)?</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do you take any opioids?</p><p>&nbsp;</p><p>The use of certain medicines, including antidepressants and opioids, together with Zyvox can lead to serotonin syndrome, a potentially life-threatening condition (see section 2 &ldquo;Other medicines and Zyvox&rdquo; and section 4).</p><p>&nbsp;</p><p><strong>Take special care with Zyvox </strong></p><p>Tell your doctor before you take this medicine if<strong> </strong>you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruise and bleed easily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are anaemic (have low red blood cells)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are prone to getting infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have a history of seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have liver problems or kidney problems particularly if you are on dialysis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have diarrhoea</p><p>&nbsp;</p><p>Tell your doctor immediately if during treatment you suffer from:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; problems with your vision such as blurred vision, changes in colour vision, difficulty in seeing detail or if your field of vision becomes restricted.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of sensitivity in your arms or legs or a sensation of tingling or pricking in your arms or legs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you may develop diarrhoea while taking or after taking antibiotics, including Zyvox. If this becomes severe or persistent or you notice that your stool contains blood or mucus, you should stop taking Zyvox immediately and consult your doctor. In this situation, you should not take medicines that stop or slow bowel movement.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; recurrent nausea or vomiting, abdominal pain or rapid breathing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unexplained muscle pain, tenderness, or weakness, and/or dark urine. These can be signs of a serious condition called rhabdomyolysis (muscle breakdown), which can lead to kidney damage.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick and unwell with muscle weakness, headache, confusion, and memory impairment which may indicate hyponatraemia (low blood sodium levels).</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Zyvox</strong></p><p>There is a risk that Zyvox may sometimes interact with certain other medicines to cause side effects such as changes in blood pressure, temperature or heart rate.</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.</p><p>&nbsp;</p><p><strong>Tell your doctor if you are taking or have taken within the last 2 weeks</strong> the following medicines as Zyvox <strong>must not</strong> be taken if you are already taking these medicines or have taken them recently (see also Section 2 above &lsquo;Do not take Zyvox&rsquo;).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; monoamine oxidase inhibitors (MAOIs for example phenelzine, isocarboxazid, selegiline, moclobemide). These may be used to treat depression or Parkinson&rsquo;s disease.</p><p>&nbsp;</p><p>Also tell your doctor if you are taking the following medicines. Your doctor may still decide to give you Zyvox, but will need to check your general health and your blood pressure before and during your treatment. In other cases, your doctor may decide that another treatment is better for you.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decongestant cold or flu remedies containing pseudoephedrine or phenylpropanolamine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some medicines used to treat asthma such as salbutamol, terbutaline, fenoterol.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain antidepressants known as tricyclics or SSRIs (selective serotonin reuptake inhibitors). There are many of these, including amitriptyline, citalopram, clomipramine, dosulepin, doxepin, fluoxetine, fluvoxamine, imipramine, lofepramine, paroxetine, sertraline.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat migraine such as sumatriptan and zolmitriptan.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat sudden, severe allergic reactions such as adrenaline (epinephrine).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines which increase your blood pressure, such as noradrenaline (norepinephrine), dopamine and dobutamine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Opioids e.g., pethidine &ndash; used to treat moderate to severe pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat anxiety disorders, such as buspirone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that stop blood clotting, such as warfarin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An antibiotic called rifampicin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines used to treat high blood pressure, heart failure and oedema (build-up of fluid in the body) called diuretics (also called &lsquo;water&rsquo; tablets).</p><p><strong>&nbsp;</strong></p><p><strong>Zyvox with food, drink and alcohol</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take Zyvox either before, during or after a meal.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid eating large amounts of mature cheese, yeast extracts, or soya bean extracts e.g., soy sauce and drinking alcohol, especially draught beers and wine. This is because Zyvox may react with a substance called tyramine which is naturally present in some foods. This interaction may cause an increase in your blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you develop a throbbing headache after eating or drinking, tell your doctor, pharmacist or nurse immediately.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>The effect of Zyvox in pregnant women is not known. Therefore, it should not be taken in pregnancy unless advised by your doctor. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>You should not breast-feed when taking Zyvox<strong> </strong>because it passes into breast milk and could affect the baby.</p><p><em>&nbsp;</em></p><p><strong>Driving and using machines</strong></p><p>Zyvox may make you feel dizzy or experience problems with your vision. If this happens, do not drive or operate any machinery. Remember that if you are unwell your ability to drive or operate machinery may be affected.</p><p>&nbsp;</p><p><strong>Zyvox contains: </strong></p><p><strong>Dextrose</strong></p><p>Zyvox solution contains Dextrose.</p><p>Please tell your doctor or nurse if you are diabetic.</p><p>&nbsp;</p><p><strong>Sodium</strong></p><p>Zyvox solution contains sodium.</p><p>Please tell your doctor or nurse if you are on a low sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Adults and Adolescents </strong></p><p>&nbsp;</p><p>Always use this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>&nbsp;</p><p>This medicine will be given to you through a drip (by infusion into a vein) by a doctor or healthcare professional.&nbsp; The recommended dose for adults and Adolescents (12 years and older) is 300 ml (600 mg linezolid) twice daily which is given directly into the blood stream (intravenously) by a drip over a period of 30 to 120 minutes.</p><p>&nbsp;</p><p>If you are on kidney dialysis, you should use Zyvox after your dialysis treatment.</p><p>&nbsp;</p><p>A course of treatment usually lasts 10 to 14 days but can last up to 28 days. The safety and effectiveness of this medicine have not been established for treatment periods longer than 28 days. Your doctor will decide how long you should be treated.</p><p><strong>&nbsp;</strong></p><p>While you are taking Zyvox, your doctor should perform regular blood tests to monitor your blood count.</p><p>&nbsp;</p><p>Your doctor should monitor your eyesight if you take Zyvox for more than 28 days.</p><p><strong>&nbsp;</strong></p><p><strong>Use in children</strong>Zyvox<strong> </strong>will be given to your child via a drip (by infusion into a vein) by a doctor or healthcare professional.&nbsp; The recommended dose for Children (date of birth though 11 years) is 10 mg/kg every 8 hours given directly into the blood stream (intravenously) by a drip over a period of 30 to 120 minutes.</p><p>&nbsp;</p><p><strong>If you take more </strong><strong>Zyvox than you should</strong></p><p>If you are concerned that you may have been given too much Zyvox, tell your doctor or a nurse at once.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to use </strong><strong>Zyvox</strong></p><p>As you will be given this medicine under close supervision, it is very unlikely that you will miss a dose. If you think that you have missed a dose of treatment, tell a doctor or nurse at once. Do not take a double dose to make up for a forgotten dose.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor, nurse or pharmacist immediately</strong> if you notice any of these side effects during your treatment with Zyvox:</p><p>&nbsp;</p><p>The serious side effects (with frequency in brackets) of Zyvox are:</p><p>&nbsp;</p><ul><li>Severe skin disorder (not known), swelling, particularly around the face and neck (not known), wheezing and/or difficulty breathing (not known). This may be the sign of an allergic reaction and it may be necessary for you to stop using Zyvox. Skin reactions such as red sore skin and flaking (dermatitis) (uncommon), rash (common), itching (common).</li><li>Problems with your vision such as blurred vision (uncommon), changes in colour vision (not known), difficulty in seeing detail (not known) or if your field of vision becomes restricted (rare).</li><li>Severe diarrhoea containing blood and/or mucus (antibiotic associated colitis including pseudomembranous colitis), which in rare circumstances may develop into complications that are life-threatening (uncommon).</li><li>Recurrent nausea or vomiting, abdominal pain or rapid breathing (rare).</li><li>Fits or seizures (uncommon) have been reported with Zyvox.</li><li>Serotonin syndrome (not known): You should let your doctor know if you experience agitation, confusion, delirium, rigidity, tremor, incoordination and seizure, rapid heartbeat, severe breathing problems, and diarrhoea (suggestive of serotonin syndrome) while also taking antidepressants known as SSRIs and Opioids (see section 2)</li><li>Unexplained bleeding or bruising, which may be due to changes in the numbers of certain cells in the blood which may affect blood clotting or lead to anaemia (common).</li><li>Changes in numbers of certain cells in the blood which may affect your ability to fight infection (uncommon) some signs of infection include: any fever (common), sore throat (uncommon), mouth ulcers (uncommon) and tiredness (uncommon).</li><li>Rhabdomyolysis (rare): Signs and symptoms include unexplained muscle pain, tenderness, or weakness, and/or dark urine. These can be signs of a serious condition called rhabdomyolysis (muscle breakdown), which can lead to kidney damage.</li><li>Inflammation of the pancreas (uncommon).</li><li>Convulsions (uncommon).</li><li>Transient ischaemic attacks (temporary disturbance of blood flow to the brain causing short term symptoms such as loss of vision, leg and arm weakness, slurring of speech and loss of consciousness) (uncommon).</li><li>&ldquo;Ringing&rdquo; in the ears (tinnitus) (uncommon).</li></ul><p>&nbsp;</p><p>Numbness, tingling or blurred vision have been reported by patients who have been given Zyvox for more than 28 days. If you experience difficulties with your vision you should consult your doctor as soon as possible.</p><p>&nbsp;</p><p><strong>Other side effects include:</strong></p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infections especially vaginal or oral &ldquo;thrush&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Metallic taste in the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, nausea or vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Changes in some blood test results including those measuring proteins, salts or enzymes which measure your kidney or liver function or blood sugar levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in sleeping</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (low red blood cell)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Localised or general abdominal pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Localised pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in platelets</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the vagina or genital area in women</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Sensations such as tingling or feeling numb</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Swollen, sore, or discoloured tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Pain at and around the place where the infusion (drip) was given</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the veins (including where the infusion (drip) was given)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; A need to urinate more often</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Feeling thirsty</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Increased sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyponatraemia (low blood sodium levels)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal bloating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in creatinine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in heart rate (e.g., increase rate)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease of the blood cell count</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weakness and/or sensory changes</p><p><strong>&nbsp;</strong></p><p><strong>Rare (may affect up to 1 in 1,000 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Superficial tooth discolouration, removable with professional dental cleaning (manual descaling)</p><p><strong>&nbsp;</strong></p><p><strong>The following side effects have also been reported (Not known: frequency cannot be estimated from the available data):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alopecia (hair loss)</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>To report any side effects:</u></strong></p><p><strong><u>&nbsp;</u></strong></p><ul><li><strong>Saudi Arabia</strong></li></ul><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not store above 25&ordm;C.</p><p>Do not use medicine after the expiry date which is stated on the carton, bags and/ or overwrap after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Hospital Staff will make sure that Zyvox Solution is not used after the &lsquo;EXP&rsquo; date printed on the bag and that it is given to you as soon as the seal is broken. They will also visually inspect the solution prior to use and only clear solution, without particles will be used. They will also make sure that the solution is kept correctly in its box and foil wrapping in order to protect from light and out of the sight and reach of children until it is needed.</p><p>&nbsp;</p><p>After opening:</p><p>From a microbiological point of view, unless the method of opening precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-The active substance is linezolid. Each 1 ml of solution contains 2 mg linezolid. Each 300 ml infusion bag contains 600 mg linezolid.</p><p>-The other ingredients are Dextrose monohydrate, sodium citrate dihydrate, citric acid anhydrous, and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zyvox is presented as a clear solution in single infusion bags containing 300 ml of solution.
The bags are supplied in boxes of 10 bags.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>&nbsp;Pfizer Inc, New York, United States.</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>HP Halden Pharma AS, Halden, Norway.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                June 2024.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">زيفوكس هو مضاد حيوي من فئة الأكسازوليدينونات، وهو يعمل من خلال إيقاف نمو بعض أنواع البكتيريا (الجراثيم) التي تسبب الإصابة بالعدوى. يستخدم<strong> </strong>زيفوكس لعلاج الالتهاب الرئوي، وبعض العدوى الجلدية أو تحت الجلدية، وبعض حالات العدوى المقاومة لفانكوميسين. سيقرر طبيبك إذا كان زيفوكس ملائمًا لعلاج العدوى التي تعاني منها أم لا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><thead><tr><td style="vertical-align:top">&nbsp;</td></tr></thead><tbody><tr><td style="vertical-align:bottom"><p dir="RTL"><strong>موانع استعمال زيفوكس:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه لينيزوليد أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول، أو تناولت خلال الأسبوعين الماضيين، أي أدوية تُعرف بأنها مثبطة لأكسيداز أحادي الأمين (MAOI: مثل فينيلزين، أيزوكاربوكسازيد، سيليجيلين، موكلوبيميد). قد تستخدم هذه الأدوية لعلاج الاكتئاب أو داء باركنسون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تُرضعين رضاعة طبيعية. وذلك لأن زيفوكس يمر إلى لبن الثدي وقد يؤثر على الطفل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال زيفوكس</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل تلقي زيفوكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يكون زيفوكس<strong> </strong>مناسبًا لعلاجك إذا أجبت <strong>بنعم</strong> على أي من الأسئلة التالية. أبلغ طبيبك في هذه الحالة، فقد يحتاج لفحص حالتك الصحية العامة وقياس ضغط دمك قبل وأثناء العلاج أو قد يقرر استخدام علاج آخر أكثر ملاءمةً لحالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اسأل طبيبك إذا لم تكن متأكدًا مما إذا كانت إحدى الفئات التالية تنطبق عليك أم لا.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp; هل أنت مصاب بضغط الدم المرتفع، سواء كنت تتناول أدوية لعلاجه أم لا؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تم تشخيصك بغدة درقية مفرطة النشاط؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل أنت مصاب بورم في الغدد الكظرية (الفيوكروموسيتوما) أو من متلازمة سرطاوية (تسببها الأورام التي تصيب الجهاز الهرموني وتصحبها أعراض الإسهال، احمرار البشرة، أزيز)؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من اكتئاب هوسي، أو اضطراب فصامي عاطفي، أو التباس عقلي، أو مشاكل عقلية أخرى؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل لديك تاريخ من الإصابة بنقص صوديوم الدم (انخفاض مستويات الصوديوم في الدم)؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تتناول أي مواد أفيونية؟</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يؤدي استخدام بعض الأدوية، بما في ذلك مضادات الاكتئاب والمواد الأفيونية، مع زيفوكس إلى الإصابة بمتلازمة السيروتونين، وهي حالة يحتمل أن تكون مهددة للحياة (انظر القسم ٢ &quot;التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية&quot; والقسم ٤).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توخَّ الحذر عند استخدام زيفوكس</strong></p><p dir="RTL">أخبر طبيبك المعالج قبل أن تتلقى هذا الدواء<strong> </strong>إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت سريع التكدم والنزيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بفقر الدم (انخفاض عدد خلايا الدم الحمراء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت عرضة للإصابة بالعدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك تاريخ من الإصابة بالنوبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات في الكبد أو الكلى، خاصة إذا كنت تخضع للديلزة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بالإسهال</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا ما أصبت بأي مما يلي أثناء العلاج:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات بصرية كتغيم الرؤية، أو تغيرات في رؤية الألوان، أو صعوبة في رؤية التفاصيل، أو إذا ما أصبح مجال رؤيتك محدودًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الحساسية في ذراعيك أو ساقيك أو الشعور بالوخز أو التنميل في ذراعيك أو ساقيك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصاب بالإسهال أثناء أو بعد تناول المضادات الحيوية، بما في ذلك زيفوكس. إذا ما أصبحت حالة الإسهال شديدة أو مستمرة أو إذا لاحظت أن البراز يحتوي على دم أو مخاط، ينبغي عليك التوقف فورًا عن تلقي زيفوكس واستشارة طبيبك. في هذه الحالة، ينبغي ألا تتناول أدوية توقف حركة الأمعاء أو تبطئها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان أو القيء المتكرران، أو ألم البطن، أو سرعة التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو وجع أو ضعف غير معروف السبب في العضلات، وبول داكن اللون أو كلاهما. قد تكون هذه علامات على الإصابة بحالة خطيرة تسمى انحلال الربيدات (انحلال العضلات)، يمكن أن تؤدي إلى تلف الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان والتوعك مع ضعف العضلات، والصداع، والارتباك وضعف الذاكرة، مما قد يشير إلى الإصابة بنقص صوديوم الدم (انخفاض مستويات الصوديوم في الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">هناك خطر أن زيفوكس قد يتفاعل أحيانًا مع بعض الأدوية الأخرى مسببًا ظهور آثار جانبية مثل تغيرات في ضغط الدم، أو درجة الحرارة، أو معدل ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أبلغ طبيبك إذا كنت تتناول أو سبق خلال الأسبوعين الماضيين</strong> أن تناولت الأدوية التالية، لأنه <strong>يجب عدم</strong> تناول زيفوكس إذا كنت تتناول هذه الأدوية بالفعل أو قد تناولتها مؤخرًا (انظر أيضًا القسم ٢ أعلاه &quot;لا تتناول زيفوكس في الحالات الآتية&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات أكسيداز أحادي الأمين (MAOIs مثل فينيلزين، أيزوكاربوكسازيد، سيليجيلين، موكلوبيميد). قد تستخدم هذه الأدوية لعلاج الاكتئاب أو داء باركنسون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كذلك أبلغ طبيبك إذا كنت تتناول الأدوية التالية. فقد يقرر طبيبك إعطاءك زيفوكس بالرغم من ذلك، ولكنه سيحتاج لفحص حالتك الصحية العامة وقياس ضغط دمك قبل وأثناء العلاج. وفي حالات أخرى، قد يقرر الطبيب إعطاءك علاجًا آخر أكثر ملاءمة لحالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج البرد والإنفلونزا المزيلة للاحتقان التي تحتوي على سودوإيفيدرين أو فينيل بروبانولامين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أدوية المستخدمة لعلاج الربو مثل سالبوتامول، تيربوتالين، فينوتيرول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الاكتئاب المعروفة باسم ثلاثيات الحلقات أو SSRIs (مثبطات استرداد السيروتونين الانتقائية). تنتمي الكثير من الأدوية لهذه الفئة بما في ذلك أميتريبتيلين، سيتالوبرام، كلوميبرامين، دوسوليبين، دوكسيبين، فلوكسيتين، فلوفوكسامين، إميبرامين، لوفيبرامين، باروكسيتين، سيرترالين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الصداع النصفي مثل سوماتريبتان وزولميتريبتان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج تفاعلات الحساسية المفاجئة الشديدة مثل الأدرينالين (إبينفرين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الرافعة لضغط الدم مثل نورأدرينالين (نورإبينفرين)، ودوبامين، ودوبيوتامين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الأفيونية مثل بيثيدين؛ المستخدمة لعلاج الألم متوسط الحدة إلى الشديد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج اضطرابات القلق، مثل بوسبيرون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي توقف تخثر الدم، مثل وارفارين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادًا حيويًا يُدعى ريفامبيسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج ضغط الدم المرتفع، وفشل القلب، والتورم (تراكم السوائل في الجسم) المسماة مدرات البول (تسمى أيضًا أقراص &quot;الماء&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول زيفوكس مع الطعام والشراب</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول زيفوكس سواء قبل أو أثناء الوجبات أو بعدها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب تناول كميات كبيرة من الجبن المعتّق، أو مستخلصات الخميرة، أو مستخلصات فول الصويا مثل صوص الصويا وكذلك تجنب شرب الكحوليات خاصة الجعة والنبيذ اللذين يتم صبهما من البرميل. تنبغي مراعاة ذلك نظرًا لإمكانية تفاعل زيفوكس مع مادة تُدعى تيرامين، وهي مادة طبيعية توجد في بعض الأطعمة. ويمكن أن يتسبب هذا التفاعل في زيادة ضغط دمك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ما أصبت بصداع نابض بعد تناول بعض الأطعمة أو المشروبات، فأبلغ طبيبك أو الصيدلي أو الممرضة على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إن تأثير زيفوكس على السيدات الحوامل غير معروف. لذا ينبغي عدم تناوله أثناء الحمل إلا إذا نصحكِ طبيبكِ بذلك. إذا كنتِ حاملًا أو تُرضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">ينبغي ألا ترضعي طفلكِ طبيعيًا أثناء تلقي زيفوكس<strong> </strong>حيث إنه قد يُفرز في لبن الأم وقد يؤثر على الطفل الرضيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير زيفوكس على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يجعلك زيفوكس تشعر بالدوار أو تصاب بمشكلات في الرؤية. إذا حدث ذلك، فامتنع عن القيادة أو تشغيل أي ماكينات. تذكر أنه إذا كنت تشعر بالتوعك، فقد تتأثر قدرتك على القيادة أو تشغيل الماكينات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات زيفوكس:</strong></p><p dir="RTL"><strong>الدكستروز </strong></p><p dir="RTL">يحتوي محلول زيفوكس على الدكستروز.</p><p dir="RTL">يرجى إخبار طبيبك أو الممرضة إذا كنت مصابًا بمرض السكري.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الصوديوم</strong></p><p dir="RTL">يحتوي محلول زيفوكس على الصوديوم.</p><p dir="RTL">يرجى إخبار طبيبك أو الممرضة إذا كنت تتبع نظامًا غذائيًا قليل الصوديوم.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>البالغون </strong><strong>&nbsp;و المراهقون </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">احرص دومًا على استخدام هذا الدواء تمامًا كما هو موضح في هذه النشرة أو كما أخبرك طبيبك أو الصيدلي أو الممرضة. راجع طبيبك أو الصيدلي أو الممرضة إذا كنت غير متأكد مما ينبغي عليك فعله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتم إعطاؤك هذا الدواء عن طريق التنقيط (بالتسريب داخل أحد الأوردة) بواسطة طبيب أو متخصص رعاية صحية.&nbsp; الجرعة الموصى بها للبالغين و المراهقون (١٢ عامًا أو أكبر) هي ٣٠٠ مل (٦٠٠ ملجم لينيزوليد) مرتين يوميًا تعطى مباشرة في مجرى الدم (عن طريق الوريد) بالتنقيط على مدار ٣٠ إلى ١٢٠ دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تخضع لديلزة الكلى، ينبغي استخدام زيفوكس بعد انتهاء العلاج بالديلزة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">غالبًا ما يستغرق العلاج ١٠ إلى ١٤ يومًا ولكنه قد يمتد ليصل إلى ٢٨ يومًا. لم يتم إثبات سلامة وفعالية هذا الدواء عند استخدامه لفترات علاجية أطول من ٢٨ يومًا. سيقرر طبيبك المدة اللازمة لعلاجك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء تلقي زيفوكس، ينبغي للطبيب إجراء فحوصات دم منتظمة لمراقبة تعداد خلايا الدم لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي أن يقوم طبيبك بمتابعة الكفاءة البصرية لديك إذا تناولت زيفوكس لمدة أطول من ٢٨ يومًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاستخدام في الأطفال </strong></p><p dir="RTL">سيتم<strong> </strong>إعطاؤك زيفوكس عن طريق التنقيط (بالتسريب داخل أحد الأوردة) بواسطة طبيب أو متخصص رعاية صحية.&nbsp; الجرعة الموصى بها بالنسبة للأطفال (منذ الولادة حتى ١١ سنة) هي ١٠ ملجم/كلجم كل ٨ ساعات تعطى مباشرة في مجرى الدم (عن طريق الوريد) بالتنقيط على مدار ٣٠ إلى ١٢٠ دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من زيفوكس</strong></p><p dir="RTL">إذا كنت تشعر بالقلق من احتمال تلقيك كمية أكبر مما ينبغي من زيفوكس، فأخبر طبيبك أو الممرضة فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة زيفوكس</strong></p><p dir="RTL">نظرًا لأنك سوف تتلقى هذا الدواء تحت إشراف دقيق، فمن المستبعد للغاية أن تفوتك إحدى الجرعات. إذا اعتقدت أنك قد فوتّ إحدى جرعات العلاج، فأخبر طبيبًا أو ممرضة على الفور. لا تأخذ جرعة مضاعفة لتعويض جرعة منسية.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><thead><tr><td style="vertical-align:top">&nbsp;</td></tr></thead><tbody><tr><td style="vertical-align:bottom"><p dir="RTL"><strong>موانع استعمال زيفوكس:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية تجاه لينيزوليد أو أي مكون آخر من مكونات هذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول، أو تناولت خلال الأسبوعين الماضيين، أي أدوية تُعرف بأنها مثبطة لأكسيداز أحادي الأمين (MAOI: مثل فينيلزين، أيزوكاربوكسازيد، سيليجيلين، موكلوبيميد). قد تستخدم هذه الأدوية لعلاج الاكتئاب أو داء باركنسون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تُرضعين رضاعة طبيعية. وذلك لأن زيفوكس يمر إلى لبن الثدي وقد يؤثر على الطفل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال زيفوكس</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي أو الممرضة قبل تلقي زيفوكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يكون زيفوكس<strong> </strong>مناسبًا لعلاجك إذا أجبت <strong>بنعم</strong> على أي من الأسئلة التالية. أبلغ طبيبك في هذه الحالة، فقد يحتاج لفحص حالتك الصحية العامة وقياس ضغط دمك قبل وأثناء العلاج أو قد يقرر استخدام علاج آخر أكثر ملاءمةً لحالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اسأل طبيبك إذا لم تكن متأكدًا مما إذا كانت إحدى الفئات التالية تنطبق عليك أم لا.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp; هل أنت مصاب بضغط الدم المرتفع، سواء كنت تتناول أدوية لعلاجه أم لا؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تم تشخيصك بغدة درقية مفرطة النشاط؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل أنت مصاب بورم في الغدد الكظرية (الفيوكروموسيتوما) أو من متلازمة سرطاوية (تسببها الأورام التي تصيب الجهاز الهرموني وتصحبها أعراض الإسهال، احمرار البشرة، أزيز)؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تعاني من اكتئاب هوسي، أو اضطراب فصامي عاطفي، أو التباس عقلي، أو مشاكل عقلية أخرى؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل لديك تاريخ من الإصابة بنقص صوديوم الدم (انخفاض مستويات الصوديوم في الدم)؟</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هل تتناول أي مواد أفيونية؟</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يؤدي استخدام بعض الأدوية، بما في ذلك مضادات الاكتئاب والمواد الأفيونية، مع زيفوكس إلى الإصابة بمتلازمة السيروتونين، وهي حالة يحتمل أن تكون مهددة للحياة (انظر القسم ٢ &quot;التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية&quot; والقسم ٤).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توخَّ الحذر عند استخدام زيفوكس</strong></p><p dir="RTL">أخبر طبيبك المعالج قبل أن تتلقى هذا الدواء<strong> </strong>إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت سريع التكدم والنزيف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بفقر الدم (انخفاض عدد خلايا الدم الحمراء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت عرضة للإصابة بالعدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك تاريخ من الإصابة بالنوبات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات في الكبد أو الكلى، خاصة إذا كنت تخضع للديلزة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا بالإسهال</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا ما أصبت بأي مما يلي أثناء العلاج:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات بصرية كتغيم الرؤية، أو تغيرات في رؤية الألوان، أو صعوبة في رؤية التفاصيل، أو إذا ما أصبح مجال رؤيتك محدودًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الحساسية في ذراعيك أو ساقيك أو الشعور بالوخز أو التنميل في ذراعيك أو ساقيك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تصاب بالإسهال أثناء أو بعد تناول المضادات الحيوية، بما في ذلك زيفوكس. إذا ما أصبحت حالة الإسهال شديدة أو مستمرة أو إذا لاحظت أن البراز يحتوي على دم أو مخاط، ينبغي عليك التوقف فورًا عن تلقي زيفوكس واستشارة طبيبك. في هذه الحالة، ينبغي ألا تتناول أدوية توقف حركة الأمعاء أو تبطئها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان أو القيء المتكرران، أو ألم البطن، أو سرعة التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو وجع أو ضعف غير معروف السبب في العضلات، وبول داكن اللون أو كلاهما. قد تكون هذه علامات على الإصابة بحالة خطيرة تسمى انحلال الربيدات (انحلال العضلات)، يمكن أن تؤدي إلى تلف الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان والتوعك مع ضعف العضلات، والصداع، والارتباك وضعف الذاكرة، مما قد يشير إلى الإصابة بنقص صوديوم الدم (انخفاض مستويات الصوديوم في الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">هناك خطر أن زيفوكس قد يتفاعل أحيانًا مع بعض الأدوية الأخرى مسببًا ظهور آثار جانبية مثل تغيرات في ضغط الدم، أو درجة الحرارة، أو معدل ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أبلغ طبيبك إذا كنت تتناول أو سبق خلال الأسبوعين الماضيين</strong> أن تناولت الأدوية التالية، لأنه <strong>يجب عدم</strong> تناول زيفوكس إذا كنت تتناول هذه الأدوية بالفعل أو قد تناولتها مؤخرًا (انظر أيضًا القسم ٢ أعلاه &quot;لا تتناول زيفوكس في الحالات الآتية&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات أكسيداز أحادي الأمين (MAOIs مثل فينيلزين، أيزوكاربوكسازيد، سيليجيلين، موكلوبيميد). قد تستخدم هذه الأدوية لعلاج الاكتئاب أو داء باركنسون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كذلك أبلغ طبيبك إذا كنت تتناول الأدوية التالية. فقد يقرر طبيبك إعطاءك زيفوكس بالرغم من ذلك، ولكنه سيحتاج لفحص حالتك الصحية العامة وقياس ضغط دمك قبل وأثناء العلاج. وفي حالات أخرى، قد يقرر الطبيب إعطاءك علاجًا آخر أكثر ملاءمة لحالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج البرد والإنفلونزا المزيلة للاحتقان التي تحتوي على سودوإيفيدرين أو فينيل بروبانولامين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أدوية المستخدمة لعلاج الربو مثل سالبوتامول، تيربوتالين، فينوتيرول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مضادات الاكتئاب المعروفة باسم ثلاثيات الحلقات أو SSRIs (مثبطات استرداد السيروتونين الانتقائية). تنتمي الكثير من الأدوية لهذه الفئة بما في ذلك أميتريبتيلين، سيتالوبرام، كلوميبرامين، دوسوليبين، دوكسيبين، فلوكسيتين، فلوفوكسامين، إميبرامين، لوفيبرامين، باروكسيتين، سيرترالين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الصداع النصفي مثل سوماتريبتان وزولميتريبتان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج تفاعلات الحساسية المفاجئة الشديدة مثل الأدرينالين (إبينفرين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الرافعة لضغط الدم مثل نورأدرينالين (نورإبينفرين)، ودوبامين، ودوبيوتامين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الأفيونية مثل بيثيدين؛ المستخدمة لعلاج الألم متوسط الحدة إلى الشديد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج اضطرابات القلق، مثل بوسبيرون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي توقف تخثر الدم، مثل وارفارين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادًا حيويًا يُدعى ريفامبيسين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج ضغط الدم المرتفع، وفشل القلب، والتورم (تراكم السوائل في الجسم) المسماة مدرات البول (تسمى أيضًا أقراص &quot;الماء&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول زيفوكس مع الطعام والشراب</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول زيفوكس سواء قبل أو أثناء الوجبات أو بعدها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب تناول كميات كبيرة من الجبن المعتّق، أو مستخلصات الخميرة، أو مستخلصات فول الصويا مثل صوص الصويا وكذلك تجنب شرب الكحوليات خاصة الجعة والنبيذ اللذين يتم صبهما من البرميل. تنبغي مراعاة ذلك نظرًا لإمكانية تفاعل زيفوكس مع مادة تُدعى تيرامين، وهي مادة طبيعية توجد في بعض الأطعمة. ويمكن أن يتسبب هذا التفاعل في زيادة ضغط دمك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ما أصبت بصداع نابض بعد تناول بعض الأطعمة أو المشروبات، فأبلغ طبيبك أو الصيدلي أو الممرضة على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إن تأثير زيفوكس على السيدات الحوامل غير معروف. لذا ينبغي عدم تناوله أثناء الحمل إلا إذا نصحكِ طبيبكِ بذلك. إذا كنتِ حاملًا أو تُرضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملًا أو تخططين للإنجاب، فاستشيري طبيبكِ أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">ينبغي ألا ترضعي طفلكِ طبيعيًا أثناء تلقي زيفوكس<strong> </strong>حيث إنه قد يُفرز في لبن الأم وقد يؤثر على الطفل الرضيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير زيفوكس على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يجعلك زيفوكس تشعر بالدوار أو تصاب بمشكلات في الرؤية. إذا حدث ذلك، فامتنع عن القيادة أو تشغيل أي ماكينات. تذكر أنه إذا كنت تشعر بالتوعك، فقد تتأثر قدرتك على القيادة أو تشغيل الماكينات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات زيفوكس:</strong></p><p dir="RTL"><strong>الدكستروز </strong></p><p dir="RTL">يحتوي محلول زيفوكس على الدكستروز.</p><p dir="RTL">يرجى إخبار طبيبك أو الممرضة إذا كنت مصابًا بمرض السكري.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الصوديوم</strong></p><p dir="RTL">يحتوي محلول زيفوكس على الصوديوم.</p><p dir="RTL">يرجى إخبار طبيبك أو الممرضة إذا كنت تتبع نظامًا غذائيًا قليل الصوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p dir="RTL"><strong>٤.</strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو الممرضة أو الصيدلي فورًا</strong> إذا لاحظت أيًا من هذه الآثار الجانبية أثناء علاجك بزيفوكس:</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الخطيرة (معدل تكرارها مكتوب بين قوسين) لزيفوكس هي:</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL">اضطراب جلدي شديد (غير معروف)، تورم، خاصة حول الوجه والرقبة (غير معروف)، أزيز و/أو صعوبة في التنفس (غير معروف). قد يكون هذا الأمر علامة على الإصابة بتفاعل حساسية وقد يكون من الضروري أن تتوقف عن استخدام زيفوكس. تفاعلات جلدية مثل احمرار وتقرح الجلد وتقشره (التهاب الجلد) (غير شائعة)، الطفح الجلدي (شائعة)، الحكة (شائعة).</li><li dir="RTL">مشكلات في الرؤية مثل تغيم الرؤية (غير شائعة)، أو تغيرات في رؤية الألوان (غير معروف)، أو صعوبة في رؤية التفاصيل (غير معروف)، أو إذا أصبح مجال رؤيتك محدودًا (نادرة).</li><li dir="RTL">إسهال شديد يحتوي على دم و/أو مخاط (التهاب القولون المرتبط بالمضادات الحيوية، بما في ذلك التهاب القولون ذو الأغشية الكاذبة)، وقد يتطور في حالات نادرة إلى مضاعفات تهدد الحياة (غير شائعة).</li><li dir="RTL">الغثيان أو القيء المتكرران، أو ألم البطن، أو سرعة التنفس (نادرة).</li><li dir="RTL">لقد تم الإبلاغ عن حدوث نوبات أو تشنجات (غير شائعة) مع استخدام زيفوكس.</li><li dir="RTL">متلازمة السيروتونين (غير معروف): ينبغي أن تخبر طبيبك إذا أصبت بتهيج، وارتباك، وهذيان، وتيبس، ورعاش، وعدم تناسق ونوبات، وضربات قلب سريعة، ومشكلات تنفسية شديدة، وإسهال (أعراض تشير إلى الإصابة بمتلازمة السيروتونين) أثناء تناول مضادات الاكتئاب المعروفة باسم مثبطات استرداد السيروتونين الانتقائية (SSRIs) والمواد الأفيونية بالتزامن (انظر القسم ٢)</li><li dir="RTL">نزيف أو تكدم دون سبب معروف، قد يكون نتيجة تغيرات في عدد بعض الخلايا في الدم مما قد يؤثر على تخثر الدم أو يؤدي إلى فقر الدم (شائعة).</li><li dir="RTL">تغيرات في عدد بعض الخلايا في الدم قد تؤثر على قدرتك على مكافحة العدوى (غير شائعة)، وتتضمن بعض علامات العدوى: أي حمى (شائعة)، واحتقان الحلق (غير شائعة)، وقرح الفم (غير شائعة)، والتعب (غير شائعة).</li><li dir="RTL">انحلال الربيدات (نادرة): تتضمن العلامات والأعراض ألم أو وجع أو ضعف غير معروف السبب في العضلات، وبول داكن اللون أو كلاهما. قد تكون هذه علامات على الإصابة بحالة خطيرة تسمى انحلال الربيدات (انحلال العضلات)، يمكن أن تؤدي إلى تلف الكلى.</li><li dir="RTL">التهاب البنكرياس (غير شائعة).</li></ul><p dir="RTL"><strong>&middot;&nbsp;&nbsp; </strong>&nbsp;&nbsp;&nbsp;الاختلاجات (غير شائعة).</p><ul><li dir="RTL">النوبات الإقفارية العابرة (اضطراب مؤقت في تدفق الدم إلى الدماغ يسبب أعراضًا قصيرة الأمد مثل فقدان الرؤية، وضعف الساقين والذراعين، والتلعثم في الكلام، وفقدان الوعي) (غير شائعة).</li><li dir="RTL">&quot;رنين&quot; في الأذنين (طنين الأذن) (غير شائعة).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">لقد أبلغ المرضى الذين تلقوا زيفوكس لأكثر من ٢٨ يومًا عن إصابتهم بالخدر، أو الوخز، أو تغيم الرؤية. إذا أصبت بصعوبات في رؤيتك، ينبغي أن تستشير طبيبك في أقرب وقت ممكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتضمن الآثار الجانبية الأخرى:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠ أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى الفطرية، خاصة &quot;سلاق&quot; الفم أو المهبل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بمذاق معدني في الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، أو الغثيان، أو القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في بعض نتائج فحوصات الدم، بما في ذلك تلك التي تقيس مستويات البروتينات أو الأملاح أو الإنزيمات التي تقيس وظائف كليتك أو كبدك أو مستويات سكر الدم لديك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدم (انخفاض عدد خلايا الدم الحمراء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; ألم موضعي أو عام في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بألم موضعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠ شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المهبل أو المنطقة التناسلية لدى السيدات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; أحاسيس مثل الوخز أو الشعور بالخدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; تورم اللسان أو تقرحه أو تغير لونه</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بألم في مكان إعطاء التسريب (التنقيط) وحوله</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوردة (بما في ذلك في مكان إعطاء التسريب (التنقيط))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الحاجة إلى التبول بمعدل أكثر تكرارًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; القشعريرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالعطش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; زيادة العرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص صوديوم الدم (انخفاض مستويات الصوديوم في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مستوى الكرياتينين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في معدل نبضات القلب (مثل زيادة المعدل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف و/أو تغيرات في الحواس</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة (قد تصيب ما يصل إلى شخص واحد من بين كل ١٠٠٠ شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير سطحي للون الأسنان، قابل للإزالة عند التنظيف الاحترافي للأسنان (إزالة القشور يدويًا)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تم الإبلاغ عن الآثار الجانبية التالية (غير معروف: لا يمكن تقدير معدل التكرار من البيانات المتاحة):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الثعلبة (تساقط الشعر)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً عبر نظام الإبلاغ القومي. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>للإبلاغ عن الأعراض الجانبية:</u></strong></p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL"><u>&nbsp;</u></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><ul><li dir="RTL">مركز الاتصال الموحد: ١٩٩٩٩</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li></ul><p dir="RTL"><strong>&middot;&nbsp;&nbsp; </strong>الموقع الإلكتروني:<strong> </strong>https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">-&nbsp;&nbsp; الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ عند درجة حرارة اقل من ٢٥ درجة مئوية.</p><p dir="RTL">لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية والأكياس والتغليف بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيحرص طاقم العمل في المستشفى على عدم استخدام محلول زيفوكس بعد تاريخ انتهاء الصلاحية المطبوع على الكيس وعلى إعطائه لك فور كسر آلية الغلق المحكم. كما سيقومون بالتحقق بصريًا من المحلول قبل الاستخدام، وسيتم فقط استخدام المحلول الصافي الذي لا يحتوي على جسيمات. وسيحرصون أيضًا على وضع المحلول بشكل صحيح في علبته والغلاف المعدني من أجل حمايته من الضوء والاحتفاظ به بعيدًا عن متناول ومرأى الأطفال حتى الحاجة إليه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد الفتح:</p><p dir="RTL">من وجهة نظر ميكروبيولوجية، ينبغي استخدام المنتج على الفور، إلا إذا كانت طريقة الفتح تستبعد خطر التلوث الميكروبي. إذا لم يُستخدم المنتج على الفور، فإن مسؤولية مدة وظروف التخزين أثناء الاستخدام تقع على عاتق المستخدم.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">- المادة الفعالة هي لينيزوليد. يحتوي كل ١ مل من المحلول على ٢ ملجم لينيزوليد. يحتوي كل كيس تسريب سعة ٣٠٠ مل على ٦٠٠ ملجم لينيزوليد.</p><p dir="RTL">- المكونات الأخرى هي دكستروز أحادي الهيدرات وثنائي هيدرات سيترات الصوديوم وحمض ستريك لا مائي، وماء للحقن.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">زيفوكس متاح في صورة محلول صافٍ في أكياس تسريب فردية تحتوي على ٣٠٠ مل من المحلول.</p><p dir="RTL">تتوافر الأكياس في علب تحتوي على ١٠ أكياس.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong></p><p>&nbsp;Pfizer Inc<strong>,</strong> New York, United States</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجهة المصنعة</strong></p><p>HP Halden Pharma AS, Halden, Norway</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يونيو/حزيران ٢٠٢٤
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zyvox 2 mg / ml Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion:
Each mL contains 2 mg of linezolid.

ZYVOX I.V. Injection contain linezolid, which is a synthetic antibacterial agent of the oxazolidinone class. The chemical name for linezolid is (S)-N-[[3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl] methyl]-acetamide.
The empirical formula is C16H20FN3O4. Its molecular weight is 337.35, and its chemical structure is represented below:
 
ZYVOX I.V. Injection is supplied as a ready-to-use sterile isotonic solution for intravenous infusion. Each mL contains 2 mg of linezolid. Inactive ingredients are citric acid, dextrose in an aqueous vehicle for intravenous administration, and sodium citrate. Sodium hydroxide NF and/or hydrochloric acid NF are used to adjust the pH. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion.
Linezolid single-dose, ready-to-use flexible plastic infusion bags in a foil laminate overwrap. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Nosocomial Pneumonia</strong></p><p>ZYVOX is indicated for the treatment of nosocomial pneumonia caused by <em>Staphylococcus aureus</em> (methicillin-susceptible and -resistant isolates) or <em>Streptococcus pneumoniae</em> [<em>see Clinical Studies</em>].</p><p><strong>Community-acquired Pneumonia</strong></p><p>ZYVOX is indicated for the treatment of community-acquired pneumonia caused by <em>Streptococcus pneumoniae</em>, including cases with concurrent bacteremia, or <em>Staphylococcus aureus</em> (methicillin-susceptible isolates only) [<em>see Clinical Studies</em>].</p><p><strong>Complicated Skin and Skin Structure Infections</strong></p><p>ZYVOX is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by <em>Staphylococcus aureus</em> (methicillin-susceptible and -resistant isolates), <em>Streptococcus pyogenes</em>, or <em>Streptococcus agalactiae</em>. ZYVOX has not been studied in the treatment of decubitus ulcers [<em>see Clinical Studies</em>].<strong>Vancomycin-resistant <em>Enterococcus faecium</em> Infections</strong></p><p>ZYVOX is indicated for the treatment of Vancomycin-resistant<em> Enterococcus faecium </em>infections,<strong> </strong>including cases with concurrent bacteremia [<em>see Clinical Studies</em>].</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Limitations of Use</u></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ZYVOX is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram‑negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected [<em>see Special warnings and precautions for use (4.4)</em>].</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The safety and efficacy of ZYVOX formulations given for longer than 28 days have not been evaluated in controlled clinical trials [<em>see Clinical Studies</em>].</p><p><strong><u>Usage</u></strong></p><p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dosage for ZYVOX injection for the treatment of infections is described in Table 1.</p><table border="1" cellspacing="0" cellpadding="0" style="width:640px"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 1. Dosage Guidelines for ZYVOX injection</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Infection<sup>*</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Dosage, Route, and Frequency of Administration</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Recommended Duration of Treatment (consecutive days)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Pediatric Patients</strong><sup>&dagger; </sup><strong>(Birth through 11 Years of Age)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Adults and Adolescents</strong></p><p><strong>(12 Years and Older)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Nosocomial pneumonia</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>10 mg/kg intravenously every 8 hours</p><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>600 mg intravenously every 12 hours</p><p>&nbsp;</p><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>10 to 14</p></td></tr><tr><td style="vertical-align:top"><p>Community-acquired pneumonia, including concurrent bacteremia</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and skin structure infections</p></td></tr><tr><td style="vertical-align:top"><p>Vancomycin-resistant <em>Enterococcus faecium</em> infections<em>, </em>including concurrent bacteremia</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>10 mg/kg intravenously every 8 hours</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>600 mg intravenously every 12 hours</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>14 to 28</p><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>* Due to the designated pathogens [<em>see Therapeutic indications (4.1)]</em></p><p><sup>&dagger;</sup><strong> Neonates less than 7 days</strong>: Most pre-term neonates less than 7 days of age (gestational age less than 34 weeks) have lower systemic linezolid clearance values and larger AUC values than many full-term neonates and older infants. These neonates should be initiated with a dosing regimen of 10 mg/kg every 12 hours. Consideration may be given to the use of 10 mg/kg every 8 hours regimen in neonates with a sub-optimal clinical response. All neonatal patients should receive 10 mg/kg every 8 hours by 7 days of life [<em>see Special warnings and Precautions for use (4.4) and Pharmacokinetics (5.2)]</em></p><p>The maximum dose for pediatric patients should not exceed the recommended adult dose. The recommended dose is 10&nbsp;mg&nbsp;per kg intravenously every 8 hours.</p><p><strong>Intravenous Administration</strong></p><p>ZYVOX I.V. Injection is supplied in single-dose, ready-to-use infusion bags. Parenteral drug products should be inspected visually for particulate matter prior to administration. Check for minute leaks by firmly squeezing the bag. If leaks are detected, discard the solution, as sterility may be impaired<em>.</em> Keep the containers in the overwrap until ready to use. Store at room temperature. Protect from freezing. ZYVOX I.V. Injection may exhibit a yellow color that can intensify over time without adversely affecting potency.</p><p>ZYVOX I.V. Injection should be administered by intravenous infusion over a period of 30 to 120 minutes. <u>Do not use this intravenous infusion container in series connections</u>. Additives should not be introduced into this solution. If ZYVOX I.V. Injection is to be given concomitantly with another drug, each drug should be given separately in accordance with the recommended dosage and route of administration for each product. Discard unused portion.</p><p>If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of ZYVOX I.V. Injection with an infusion solution compatible with ZYVOX I.V. Injection and with any other drug(s) administered via this common line.</p><p><strong>Compatibilities</strong></p><p>Compatible intravenous solutions include 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, and Lactated Ringer&rsquo;s Injection, USP.</p><p>Specific population</p><p>&nbsp;</p><p><strong>Pediatric Use</strong></p><p>The safety and effectiveness of ZYVOX for the treatment of pediatric patients with the following infections are supported by evidence from adequate and well-controlled studies in adults, pharmacokinetic data in pediatric patients, and additional data from a comparator-controlled study of Gram-positive infections in pediatric patients ranging in age from birth through 11 years [<em>see Posology and methods of administration (4.2), Pharmacokinetics (5.2) and Clinical Studies (5.1)</em>]:</p><ul><li>nosocomial pneumonia</li><li>complicated skin and skin structure infections</li><li>community-acquired pneumonia<em> </em>(also supported by evidence from an uncontrolled study in patients ranging in age from 8 months through 12 years)</li><li>vancomycin-resistant <em>Enterococcus faecium</em> infections</li></ul><p>Pharmacokinetic information generated in pediatric patients with ventriculoperitoneal shunts showed variable cerebrospinal fluid (CSF) linezolid concentrations following single and multiple dosing of linezolid; therapeutic concentrations were not consistently achieved or maintained in the CSF. Therefore, the use of linezolid for the empiric treatment of pediatric patients with central nervous system infections is not recommended.</p><p>The pharmacokinetics of linezolid have been evaluated in pediatric patients from birth to 17 years of age. In general, weight-based clearance of linezolid gradually decreases with increasing age of pediatric patients. However, in preterm (gestational age &lt; 34 weeks) neonates &lt; 7 days of age, linezolid clearance is often lower than in full-term neonates &lt; 7 days of age. Consequently, preterm neonates &lt; 7 days of age may need an alternative linezolid dosing regimen of 10 mg/kg every 12 hours <em>[see </em><em>Pharmacodynamic properties</em><em> (5.1)]</em>.</p><p>In limited clinical experience, 5 out of 6 (83%) pediatric patients with infections due to Gram-positive pathogens with minimum inhibitory concentrations (MICs) of 4 mcg/mL treated with ZYVOX had clinical cures. However, pediatric patients exhibit wider variability in linezolid clearance and systemic exposure (AUC) compared with adults. In pediatric patients with a sub-optimal clinical response, particularly those with pathogens with MIC of 4 mcg/mL, lower systemic exposure, site and severity of infection, and the underlying medical condition should be considered when assessing clinical response <em>[see</em> <em>Pharmacodynamic properties</em><em> (5.1)]</em>.</p><p><strong>Geriatric Use</strong></p><p>Of the 2,046 patients treated with ZYVOX in Phase 3 comparator-controlled clinical trials, 589 (29%) were 65 years or older and 253 (12%) were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity
ZYVOX injection are contraindicated for use in patients who have known hypersensitivity to linezolid or any of the other product components.
Monoamine Oxidase Inhibitors
Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Myelosuppression </strong></p><p>Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia) has been reported in patients receiving linezolid. In cases where the outcome is known, when linezolid was discontinued, the affected hematologic parameters have risen toward pretreatment levels. Thrombocytopenia has been reported more often in patients with severe renal impairment, whether or not on dialysis, and in patients with moderate to severe hepatic impairment. Complete blood counts should be monitored weekly in patients who receive linezolid, particularly in those who receive linezolid for longer than two weeks, those with pre-existing myelosuppression, those with severe renal impairment or moderate to severe hepatic impairment, those receiving concomitant drugs that produce bone marrow suppression, or those with a chronic infection who have received previous or concomitant antibacterial drug therapy. Discontinuation of therapy with linezolid should be considered in patients who develop or have worsening myelosuppression [<em>see Undesirable side effects (4.8)]</em><em>.</em></p><p><strong>&nbsp;</strong></p><p><strong>Peripheral and Optic Neuropathy</strong></p><p>Peripheral and optic neuropathies have been reported in patients treated with ZYVOX, primarily in those patients treated for longer than the maximum recommended duration of 28 days. In cases of optic neuropathy that progressed to loss of vision, patients were treated for extended periods beyond the maximum recommended duration. Visual blurring has been reported in some patients treated with ZYVOX for less than 28 days. Peripheral and optic neuropathy has also been reported in children.</p><p>If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, blurred vision, or visual field defect, prompt ophthalmic evaluation is recommended. Visual function should be monitored in all patients taking ZYVOX for extended periods (&ge; 3 months) and in all patients reporting new visual symptoms regardless of length of therapy with ZYVOX. If peripheral or optic neuropathy occurs, the continued use of ZYVOX in these patients should be weighed against the potential risks.</p><p><strong>&nbsp;</strong></p><p><strong>Serotonin Syndrome</strong></p><p>Spontaneous reports of serotonin syndrome including fatal cases associated with the co-administration of ZYVOX and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.</p><p>Unless clinically appropriate and patients are carefully observed for signs and/or symptoms of serotonin syndrome or neuroleptic malignant syndrome-like (NMS-like) reactions, linezolid should not be administered to patients with carcinoid syndrome and/or patients taking any of the following medications: serotonin re-uptake inhibitors, tricyclic antidepressants, bupropion, buspirone, serotonin 5‑HT1 receptor agonists (triptans), and opioids, including meperidine [<em>see </em><em>Interaction with other medicinal products and other forms of interaction (4.5)</em> <em>&nbsp;and Pharmacokinetics(5.2)</em>].</p><p>In some cases, a patient already receiving a serotonergic antidepressant or buspirone may require urgent treatment with linezolid. If alternatives to linezolid are not available and the potential benefits of linezolid outweigh the risks of serotonin syndrome or NMS-like reactions, the serotonergic antidepressant should be stopped promptly and linezolid administered. The patient should be monitored for two weeks (five weeks if fluoxetine was taken) or until 24 hours after the last dose of linezolid, whichever comes first. Symptoms of serotonin syndrome or NMS-like reactions include hyperthermia, rigidity, myoclonus, autonomic instability, and mental status changes that include extreme agitation progressing to delirium and coma. The patient should also be monitored for discontinuation symptoms of the antidepressant (see package insert of the specified agent(s) for a description of the associated discontinuation symptoms).</p><p><strong>&nbsp;</strong></p><p><strong>Mortality Imbalance in an Investigational Study in Patients with Catheter-Related Bloodstream Infections, Including Those with Catheter-Site Infections</strong></p><p>An imbalance in mortality was seen in patients treated with linezolid relative to vancomycin/dicloxacillin/oxacillin in an open-label study in seriously ill patients with intravascular catheter-related infections [78/363 (21.5%) vs. 58/363 (16.0%); odds ratio 1.426, 95% CI 0.970, 2.098]. While causality has not been established, this observed imbalance occurred primarily in linezolid-treated patients in whom either Gram-negative pathogens, mixed Gram-negative and Gram-positive pathogens, or no pathogen were identified at baseline, but was not seen in patients with Gram-positive infections only.</p><p>Linezolid is not approved and should not be used for the treatment of patients with catheter-related bloodstream infections or catheter-site infections.</p><p>Linezolid has no clinical activity against Gram-negative pathogens and is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected [<em>see Posology and Methods of administration (4.2)</em>].</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Clostridioides difficile</em></strong><strong> Associated Diarrhea </strong></p><p><em>Clostridioides difficile</em> Associated Diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including ZYVOX, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <em>C. difficile</em>.</p><p><em>C. difficile</em> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <em>C. difficile</em> cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.</p><p>Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p><p>If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against <em>C. difficile</em> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of <em>C. difficile</em>, and surgical evaluation should be instituted as clinically indicated.</p><p><strong>&nbsp;</strong></p><p><strong>Potential Interactions Producing Elevation of Blood Pressure </strong></p><p>Unless patients are monitored for potential increases in blood pressure, linezolid should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) [<em>see</em><em>Interaction with other medicinal products and other forms of interaction (4.5) </em><em>&nbsp;and Pharmacokinetics (5.2</em><em>)</em>]<strong>.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Lactic Acidosis</strong></p><p>Lactic acidosis has been reported with the use of ZYVOX. In reported cases, patients experienced repeated episodes of nausea and vomiting. Patients who develop recurrent nausea or vomiting, unexplained acidosis, or a low bicarbonate level while receiving ZYVOX should receive immediate medical evaluation.</p><p><strong>&nbsp;</strong></p><p><strong>Convulsions</strong></p><p>Convulsions have been reported in patients when treated with linezolid. In some of these cases, a history of seizures or risk factors for seizures was reported.</p><p><strong>&nbsp;</strong></p><p><strong>Rhabdomyolysis</strong></p><p>Rhabdomyolysis has been reported with the use of linezolid, including ZYVOX [<em>see </em><em>Undesirable side effects (4.8)</em>]. If signs or symptoms of rhabdomyolysis such as muscle pain, tenderness or weakness, dark urine or elevated creatine phosphokinase are observed, discontinue ZYVOX and initiate appropriate therapy.</p><p><strong>&nbsp;</strong></p><p><strong>Hypoglycemia</strong></p><p>Postmarketing cases of symptomatic hypoglycemia have been reported in patients with diabetes mellitus receiving insulin or oral hypoglycemic agents when treated with linezolid, a reversible, nonselective MAO inhibitor. Some MAO inhibitors have been associated with hypoglycemic episodes in diabetic patients receiving insulin or hypoglycemic agents. While a causal relationship between linezolid and hypoglycemia has not been established, diabetic patients should be cautioned of potential hypoglycemic reactions when treated with linezolid.</p><p>If hypoglycemia occurs, a decrease in the dose of insulin or oral hypoglycemic agent, or discontinuation of oral hypoglycemic agent, insulin, or linezolid may be required.</p><p><strong>&nbsp;</strong></p><p><strong>Hyponatremia and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)</strong></p><p>Postmarketing cases of hyponatremia and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) have been observed in patients treated with linezolid. In reported cases, the signs and symptoms included confusion, somnolence, generalized weakness, and in severe cases led to respiratory failure and even death. Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking ZYVOX. If signs and symptoms of hyponatremia and/or SIADH occur, discontinue ZYVOX, and institute appropriate supportive measures.</p><p><strong>&nbsp;</strong></p><p><strong>Development of Drug-Resistant Bacteria</strong></p><p>Prescribing ZYVOX in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Monoamine Oxidase Inhibitors</strong></p><p>Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. [<em>see Contraindications (4.3) and Pharmacokinetics (5.2)</em>].</p><p><strong>Adrenergic and Serotonergic Agents</strong></p><p>Linezolid has the potential for interaction with adrenergic and serotonergic agents. [<em>see Special Warnings and Precautions for use (4.2) and Pharmacokinetics (5.2)</em>].</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p><u>Risk Summary</u></p><p>Available data from published and postmarketing case reports with linezolid use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. When administered during organogenesis, linezolid did not cause malformations in mice, rats, or rabbits at maternal exposure levels approximately 6.5 times (mice),&nbsp;equivalent to (rats), or 0.06 times (rabbits) the clinical therapeutic exposure, based on AUCs. However, embryo‑fetal lethality was observed in mice at 6.5 times the estimated human exposure. When female rats were dosed during organogenesis through lactation, postnatal survival of pups was decreased at doses approximately equivalent to the estimated human exposure based on AUCs (<em>see Data</em>)<em>.</em></p><p>The background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</p><p>&nbsp;</p><p><u>Data</u></p><p><em>Animal Data</em></p><p>In mice, embryo‑fetal toxicities were observed only at doses that caused maternal toxicity (clinical signs and reduced body weight gain). An oral dose of 450 mg/kg/day given from Gestation Day (GD) 6‑16 (6.5 times the estimated human exposure based on AUCs) correlated with increased postimplantational embryo death, including total litter loss, decreased fetal body weights, and an increased incidence of costal cartilage fusion. Neither maternal nor embryo‑fetal toxicities were observed at doses up to 150 mg/kg/day. Fetal malformations were not observed.</p><p>In rats, fetal toxicity was observed at 15 and 50 mg/kg/day administered orally from GD 6‑17 (exposures 0.22&nbsp;times to approximately equivalent to the estimated human exposure, respectively, based on AUCs). The effects consisted of decreased fetal body weights and reduced ossification of sternebrae, a finding often seen in association with decreased fetal body weights. Fetal malformations were not observed. Maternal toxicity, in the form of reduced body weight gain, was seen at 50&nbsp;mg/kg/day.</p><p>In rabbits, reduced fetal body weight occurred only in the presence of maternal toxicity (clinical signs, reduced body weight gain and food consumption) when administered at an oral dose of 15 mg/kg/day given from GD&nbsp;6‑20 (0.06 times the estimated human exposure based on AUCs). Fetal malformations were not observed.</p><p>When female rats were treated with 50 mg/kg/day (approximately equivalent to the estimated human exposure based on AUCs) of linezolid during pregnancy and lactation (GD 6 through Lactation Day 20), survival of pups was decreased on postnatal days 1 to 4. Male and female pups permitted to mature to reproductive age, when mated, showed an increase in preimplantation loss.</p><p>&nbsp;</p><p>Lactation</p><p><u>Risk Summary</u></p><p>Linezolid is present in breast milk. Based on data from available published case reports, the daily dose of linezolid that the infant would receive from breastmilk would be approximately 6% to 9% of the recommended therapeutic infant dose (10 mg/kg every 8 hours). There is no information on the effects of linezolid on the breastfed infant; however, diarrhea and vomiting were the most common adverse reactions reported in clinical trials in infants receiving linezolid therapeutically [<em>see Undesirable side effects (4.8)</em> and <em>(see Clinical Considerations)]. </em>There is no information on the effects of linezolid on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for linezolid and any potential adverse effects on the breastfed child from linezolid or from the underlying maternal condition.</p><p><u>Clinical Considerations</u></p><p>Advise lactating women to monitor a breastfed infant for diarrhea and vomiting.<u> </u></p><p><u>&nbsp;</u></p><p><strong>Females and Males of Reproductive Potential</strong></p><p><u>Infertility</u></p><p><em>Males</em></p><p>Based on findings from studies in rats, ZYVOX may reversibly impair fertility in male patients<em> </em>[<em>see Nonclinical Toxicology (5.3)</em>]<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effect of linezolid on the ability to drive or operate machinery has not been systematically evaluated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following clinically significant adverse reactions are described elsewhere in the labeling:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Myelosuppression [<em>see Special warnings and precautions for use (4.4)</em>]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Peripheral and Optic Neuropathy [<em>see Special warnings and precautions for use (4.4)</em>]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Serotonin Syndrome [<em>see Special warnings and precautions for use (4.4)</em>]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <em>Clostridioides</em> <em>difficile</em>-Associated Diarrhea [<em>see Special warnings and precautions for use (4.4)</em>]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Lactic Acidosis [<em>see Special warnings and precautions for use (4.4)</em>]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Convulsions [<em>see Special warnings and precautions for use (4.4)</em>]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Rhabdomyolysis [<em>see Special warnings and precautions for use (4.4)</em>]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Hypoglycemia [<em>see Special warnings and precautions for use (4.4)</em>]</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Hyponatremia and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) [<em>see Special warnings and precautions for use (4.4)</em>]</p><p>&nbsp;</p><p><strong>Clinical Trials Experience</strong></p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><p><u>Adults:</u></p><p>The safety of ZYVOX formulations was evaluated in 2,046 adult patients enrolled in seven Phase 3 comparator-controlled clinical trials, who were treated for up to 28 days.</p><p>For all indications, 20.4% of linezolid-treated and 14.3% of comparator-treated patients experienced at least one drug-related adverse event.</p><p>Table 2 shows the incidence of all-causality, treatment-emergent adverse reactions reported in at least 1% of adult patients in these trials by dose of ZYVOX.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 2. Incidence (%) of Treatment&ndash;Emergent Adverse Reactions Occurring in greater than1% of Adult Patients Treated with ZYVOX in Comparator-Controlled Clinical Trials</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ADVERSE REACTIONS</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>ZYVOX</strong></p><p><strong>600 mg every</strong></p><p><strong>12 hours</strong></p><p><strong>(n=1498)</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>All Other Comparators*</strong></p><p><strong>(n=1464)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>5.7</p></td><td style="vertical-align:top"><p>4.4</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>8.3</p></td><td style="vertical-align:top"><p>6.4</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>6.6</p></td><td style="vertical-align:top"><p>4.6</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>2.3</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>1.5</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>2.6</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>1.4</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Taste alteration</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.3</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vaginal moniliasis</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>0.5</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Oral moniliasis</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>1.0</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Abnormal liver function tests</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>0.8</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fungal infection</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.2</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Tongue discoloration</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Localized abdominal pain</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>0.8</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Generalized abdominal pain</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.0</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>*Comparators included cefpodoxime proxetil 200 mg by mouth every 12 hours; ceftriaxone 1 g intravenously every 12 hours; dicloxacillin 500 mg by mouth every 6 hours; oxacillin 2 g intravenously every 6 hours; vancomycin 1 g intravenously every 12 hours.</p><p>&nbsp;</p><p>For other indications, discontinuations due to drug-related adverse events occurred in 2.1% of ZYVOX-treated and 1.7% of comparator-treated patients. The most common reported drug-related adverse events leading to discontinuation of treatment were nausea, headache, diarrhea, and vomiting.</p><p><u>Pediatric Patients:</u></p><p>The safety of ZYVOX formulations was evaluated in 215 pediatric patients ranging in age from birth through 11 years, and in 248 pediatric patients aged 5 through 17 years (146 of these 248 were age 5 through 11 and 102 were age 12 to 17). These patients were enrolled in two Phase 3 comparator-controlled clinical trials and were treated for up to 28 days. In the study of hospitalized pediatric patients (birth through 11 years) with Gram-positive infections, who were randomized 2 to 1 (linezolid: vancomycin), mortality was 6.0% (13/215) in the linezolid arm and 3.0% (3/101) in the vancomycin arm. However, given the severe underlying illness in the patient population, no causality could be established.</p><p>&nbsp;</p><p>For all indications, 18.8% of ZYVOX-treated and 34.3% of comparator-treated patients experienced at least one drug-related adverse event.</p><p>&nbsp;</p><p>Table 3 shows the incidence of all-causality, treatment-emergent adverse reactions reported in more than 1% of pediatric patients (and more than 1 patient) in either treatment group in the comparator-controlled Phase 3 trials.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table 3. Incidence (%) of Treatment-Emergent Adverse Reactions Occurring in greater than1% of Pediatric Patients (and greater than1 Patient) in Either Treatment Group in Comparator-Controlled Clinical Trials</strong><strong>*</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ADVERSE REACTIONS</strong></p></td><td style="vertical-align:top"><p><strong>ZYVOX<br />(n=215)</strong><br />&nbsp;</p></td><td style="vertical-align:top"><p><strong>Vancomycin<br />(n=101)</strong><br />&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>10.8</p></td><td style="vertical-align:top"><p>12.1</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>9.4</p></td><td style="vertical-align:top"><p>9.1</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>0</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>5.6</p></td><td style="vertical-align:top"><p>7.1</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>4.7</p></td><td style="vertical-align:top"><p>2.0</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>0</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Generalized abdominal pain</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>2.0</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Localized abdominal pain</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>1.0</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Loose stools</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>3.0</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eosinophilia</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>1.0</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus at non-application site</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>2.0</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*&nbsp;&nbsp; Patients from birth through 11 years of age received linezolid 10 mg/kg intravenously and/or by mouth every 8&nbsp;hours or vancomycin 10 to 15 mg/kg intravenously every 6-24 hours, depending on age and renal clearance.</p><p>&nbsp;</p></td></tr></tbody></table><p>For other indications, discontinuations due to drug‑related adverse events occurred in 0.9% of ZYVOX-treated and 6.1% of comparator-treated patients.</p><p><u>&nbsp;</u></p><p><u>Laboratory Abnormalities:</u></p><p>ZYVOX has been associated with thrombocytopenia when used in doses up to and including 600 mg every 12 hours for up to 28 days. In Phase 3 comparator-controlled trials, the percentage of adult patients who developed a substantially low platelet count (defined as less than 75% of lower limit of normal and/or baseline) was 2.4% (range among studies: 0.3 to 10.0%) with ZYVOX and 1.5% (range among studies: 0.4 to 7.0%) with a comparator. In a study of hospitalized pediatric patients ranging in age from birth through 11 years, the percentage of patients who developed a substantially low platelet count (defined as less than 75% of lower limit of normal and/or baseline) was 12.9% with ZYVOX and 13.4% with vancomycin. In an outpatient study of pediatric patients aged from 5 through 17 years, the percentage of patients who developed a substantially low platelet count was 0% with ZYVOX and 0.4% with cefadroxil. Thrombocytopenia associated with the use of ZYVOX appears to be dependent on duration of therapy (generally greater than 2 weeks of treatment). The platelet counts for most patients returned to the normal range/baseline during the follow-up period. No related clinical adverse events were identified in Phase 3 clinical trials in patients developing thrombocytopenia. Bleeding events were identified in thrombocytopenic patients in a compassionate use program for ZYVOX; the role of linezolid in these events cannot be determined [<em>see Special Warnings and Precautions for use (4.4)</em>].</p><p>Changes seen in other laboratory parameters, without regard to drug relationship, revealed no substantial differences between ZYVOX and the comparators. These changes were generally not clinically significant, did not lead to discontinuation of therapy, and were reversible. The incidence of adult and pediatric patients with at least one substantially abnormal hematologic or serum chemistry value is presented in Tables 4, 5, 6, and 7.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 4. Percent of Adult Patients who Experienced at Least One Substantially Abnormal<sup>*</sup> Hematology Laboratory Value in Comparator-Controlled Clinical Trials with ZYVOX</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Laboratory Assay</strong></p></td><td style="vertical-align:top"><p><strong>ZYVOX</strong></p><p><strong>600 mg every 12 hours</strong></p></td><td style="vertical-align:top"><p><strong>All Other Comparators<sup>&dagger;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Hemoglobin (g/dL)</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>6.6</p></td></tr><tr><td style="vertical-align:top"><p>Platelet count (x 10<sup>3</sup>/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>1.8</p></td></tr><tr><td style="vertical-align:top"><p>WBC (x 10<sup>3</sup>/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>Neutrophils (x 10<sup>3</sup>/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>1.2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*&nbsp;&nbsp;&nbsp;&nbsp; Less than 75% (less than 50% for neutrophils) of Lower Limit of Normal (LLN) for values normal at baseline; less than 75% (less than 50% for neutrophils) of LLN and of baseline for values abnormal at baseline.</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Comparators included cefpodoxime proxetil 200 mg by mouth every 12 hours; ceftriaxone 1 g intravenously every 12&nbsp;hours; dicloxacillin 500 mg by mouth every 6 hours; oxacillin 2 g intravenously every 6 hours; vancomycin 1 g intravenously every 12 hours.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Table 5. Percent of Adult Patients who Experienced at Least One Substantially Abnormal*<sup> </sup>Serum Chemistry Laboratory Value in Comparator-Controlled Clinical Trials with Linezolid</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Laboratory Assay</strong></p></td><td style="vertical-align:bottom"><p><strong>Linezolid<br />600 mg every 12 hours</strong></p></td><td style="vertical-align:bottom"><p><strong>All Other Comparators<sup>&dagger;</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>AST (U/L)</p></td><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top"><p>6.8</p></td></tr><tr><td style="vertical-align:top"><p>ALT (U/L)</p></td><td style="vertical-align:top"><p>9.6</p></td><td style="vertical-align:top"><p>9.3</p></td></tr><tr><td style="vertical-align:top"><p>LDH (U/L)</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top"><p>Alkaline phosphatase (U/L)</p></td><td style="vertical-align:top"><p>3.5</p></td><td style="vertical-align:top"><p>3.1</p></td></tr><tr><td style="vertical-align:top"><p>Lipase (U/L)</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>4.2</p></td></tr><tr><td style="vertical-align:top"><p>Amylase (U/L)</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Total bilirubin (mg/dL)</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>1.1</p></td></tr><tr><td style="vertical-align:top"><p>BUN (mg/dL)</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>1.5</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine (mg/dL)</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>0.6</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp; Greater than 2&times; Upper Limit of Normal (ULN) for values normal at baseline; greater than 2&times; ULN and greater than 2&times;&nbsp;baseline for values abnormal at baseline.</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Comparators included cefpodoxime proxetil 200 mg by mouth every 12 hours; ceftriaxone 1 g intravenously every 12&nbsp;hours; dicloxacillin 500 mg by mouth every 6 hours; oxacillin 2 g intravenously every 6 hours; vancomycin 1 g intravenously every 12 hours.</p><p><strong>&nbsp;</strong></p><p><strong>Table 6. Percent of Pediatric Patients who Experienced at Least One Substantially Abnormal* </strong></p><p><strong>Hematology Laboratory Value in Comparator-Controlled Clinical Trials with Linezolid</strong><sup>&dagger;</sup><strong> </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p><strong>Laboratory Assay</strong></p></td><td style="vertical-align:bottom"><p><strong>Linezolid</strong></p></td><td style="vertical-align:bottom"><p><strong>Vancomycin</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hemoglobin (g/dL)</p></td><td style="vertical-align:top"><p>15.7</p></td><td style="vertical-align:top"><p>12.4</p></td></tr><tr><td style="vertical-align:top"><p>Platelet count (x 10<sup>3</sup>/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>12.9</p></td><td style="vertical-align:top"><p>13.4</p></td></tr><tr><td style="vertical-align:top"><p>WBC (x 10<sup>3</sup>/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>12.4</p></td><td style="vertical-align:top"><p>10.3</p></td></tr><tr><td style="vertical-align:top"><p>Neutrophils (x 10<sup>3</sup>/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>5.9</p></td><td style="vertical-align:top"><p>4.3</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp; Less than 75% (less than 50% for neutrophils) of Lower Limit of Normal (LLN) for values normal at baseline; less than 75% (less than 50% for neutrophils) of LLN and less than 75% (less than 50% for neutrophils, less than 90% for hemoglobin if baseline less than LLN) of baseline for values abnormal at baseline.</p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients from birth through 11 years of age received linezolid 10 mg/kg intravenously and/or by mouth every 8&nbsp;hours or vancomycin 10 to 15 mg/kg intravenously every 6-24 hours, depending on age and renal clearance.</p><p><strong>Table 7. Percent of Pediatric Patients who Experienced at Least One Substantially Abnormal*<sup> </sup></strong></p><p><strong>Serum Chemistry Laboratory Value in Comparator-Controlled Clinical Trials with Linezolid<sup>&dagger;</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Laboratory Assay</strong></p></td><td style="vertical-align:bottom"><p><strong>Linezolid</strong></p></td><td style="vertical-align:bottom"><p><strong>Vancomycin</strong></p></td></tr><tr><td style="vertical-align:top"><p>ALT (U/L)</p></td><td><p>10.1</p></td><td><p>12.5</p></td></tr><tr><td style="vertical-align:top"><p>Lipase (U/L)</p></td><td><p>---</p></td><td><p>---</p></td></tr><tr><td style="vertical-align:top"><p>Amylase (U/L)</p></td><td><p>0.6</p></td><td><p>1.3</p></td></tr><tr><td style="vertical-align:top"><p>Total bilirubin (mg/dL)</p></td><td><p>6.3</p></td><td><p>5.2</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine (mg/dL)</p></td><td><p>2.4</p></td><td><p>1.0</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp; Greater than 2 x Upper Limit of Normal (ULN) for values normal at baseline; greater than 2&times; ULN and greater than 2&nbsp;(greater than 1.5 for total bilirubin) &times; baseline for values abnormal at baseline.</p><p><strong><sup>&dagger;</sup></strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Patients from birth through 11 years of age received linezolid 10 mg/kg intravenously and/or by mouth every 8&nbsp;hours or vancomycin 10 to 15 mg/kg intravenously every 6-24 hours, depending on age and renal clearance</p><p><strong>&nbsp;</strong></p><p><strong>Postmarketing Experience</strong></p><p>The following adverse reactions have been identified during postapproval use of ZYVOX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylaxis, angioedema, bullous skin disorders including severe cutaneous adverse reactions (SCAR) such as toxic epidermal necrolysis and Stevens-Johnson syndrome, and hypersensitivity vasculitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myelosuppression (including anemia, leukopenia, pancytopenia, and thrombocytopenia). Thrombocytopenia has been reported more often in patients with severe renal impairment and in patients with moderate to severe hepatic impairment [<em>see Special Warnings and Precautions for use (4.4)</em>]; sideroblastic anemia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peripheral neuropathy, and optic neuropathy sometimes progressing to loss of vision [<em>see Special Warnings and Precautions for use (4.4)</em>].</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serotonin syndrome has been reported in patients receiving concomitant serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and opioids, and ZYVOX [<em>seeSpecial Warnings and Precautions for use (4.4)</em>].</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lactic acidosis [<em>see Special Warnings and Precautions for use (4.4)</em>]. Although these reports have primarily been in patients treated for longer than the maximum recommended duration of 28 days, these events have also been reported in patients receiving shorter courses of therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsions [<em>see Special Warnings and Precautions for use (4.4)</em>].</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rhabdomyolysis [<em>see</em> <em>Warnings and Precautions for use (4.4)</em>].</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypoglycemia, including symptomatic episodes [<em>see Special Warnings and Precautions for use (4.4)</em>].</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyponatremia and/or Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) [<em>see Special Warnings and Precautions (4.4)</em>].</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Superficial tooth discoloration and tongue discoloration have been reported with the use of linezolid. The tooth discoloration was removable with professional dental cleaning (manual descaling) in cases with known outcome.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p><u>To report any side effects:</u></p><p><u>&nbsp;</u></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa<u>&nbsp;&nbsp;&nbsp; </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the event of overdosage, supportive care is advised, with maintenance of glomerular filtration. Hemodialysis may facilitate more rapid elimination of linezolid. In a Phase 1 clinical trial, approximately 30% of a dose of linezolid was removed during a 3-hour hemodialysis session beginning 3 hours after the dose of linezolid was administered. Data are not available for removal of linezolid with peritoneal dialysis or hemoperfusion.<strong> </strong>Clinical signs of acute toxicity in animals<strong> </strong>were decreased activity and ataxia in rats and vomiting and tremors in dogs treated with 3,000 mg/kg/day and 2,000 mg/kg/day, respectively.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mechanism of Action</u></p><p>Linezolid is a synthetic antibacterial agent of the oxazolidinone class,<em> </em>which has clinical utility in the treatment of infections caused by aerobic Gram-positive<em> </em>bacteria. The in vitro spectrum of activity of linezolid also includes certain Gram-negative bacteria and anaerobic bacteria. Linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is essential for bacterial reproduction. The results of time-kill studies have shown linezolid to be bacteriostatic against enterococci and staphylococci. For streptococci, linezolid was found to be bactericidal for the majority of isolates.</p><p><u>Resistance</u></p><p>In vitro studies have shown that point mutations in the 23S rRNA are associated with linezolid resistance. Reports of vancomycin-resistant <em>Enterococcus faecium</em> becoming resistant to linezolid during its clinical use have been published. There are reports of <em>Staphylococcus aureus</em> (methicillin-resistant) developing resistance to linezolid during clinical use. The linezolid resistance in these organisms is associated with a point mutation in the 23S rRNA (substitution of thymine for guanine at position 2576) of the organism. Organisms resistant to oxazolidinones via mutations in chromosomal genes encoding 23S rRNA or ribosomal proteins (L3 and L4) are generally cross-resistant to linezolid. Also linezolid resistance in staphylococci mediated by the enzyme methyltransferase has been reported. This resistance is mediated by the <em>cfr</em> (chloramphenicol-florfenicol) gene located on a plasmid which is transferable between staphylococci.</p><p><u>Interaction with Other Antimicrobial Drugs</u></p><p>In vitro studies have demonstrated additivity or indifference between linezolid and vancomycin, gentamicin, rifampin, imipenem-cilastatin, aztreonam, ampicillin, or streptomycin.</p><p>Linezolid has been shown to be active against most isolates of the following microorganisms, both in vitro and in clinical infections [<em>see Posology and methods of Administration (4.2)</em>].</p><p><u>Gram-positive bacteria</u></p><p><em>Enterococcus faecium </em>(vancomycin-resistant isolates only)</p><p><em>Staphylococcus aureus </em>(including methicillin-resistant isolates)</p><p><em>Streptococcus agalactiae</em></p><p><em>Streptococcus pneumoniae </em></p><p><em>Streptococcus pyogenes</em></p><p>The following in vitro data are available, but their clinical significance is unknown. Greater than 90% of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the linezolid-susceptible breakpoint for organisms of similar genus. The safety and effectiveness of linezolid in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.</p><p><u>Gram-positive bacteria</u></p><p><em>Enterococcus faecalis </em>(including vancomycin-resistant isolates)</p><p><em>Enterococcus faecium </em>(vancomycin-susceptible isolates)</p><p><em>Staphylococcus epidermidis</em> (including methicillin-resistant isolates)</p><p><em>Staphylococcus haemolyticus</em></p><p>Viridans group streptococci</p><p><u>Gram-negative bacteria </u></p><p><em>Pasteurella multocida</em></p><p><em>&nbsp;</em></p><p>In a randomized, positive- and placebo-controlled crossover thorough QT study, 40 healthy subjects were administered a single ZYVOX 600 mg dose via a 1 hour IV infusion, a single ZYVOX 1,200 mg dose via a 1 hour IV infusion, placebo, and a single oral dose of positive control. At both the 600 mg and 1,200 mg ZYVOX doses, no significant effect on QTc interval was detected at peak plasma concentration or at any other time.</p><p><strong><u>CLINICAL STUDIES</u></strong></p><p><strong>Adults</strong></p><p><u>Nosocomial Pneumonia</u></p><p>Adult patients with clinically and radiologically documented nosocomial pneumonia were enrolled in a randomized, multi-center, double-blind trial. Patients were treated for 7 to 21 days. One group received ZYVOX I.V. Injection 600 mg every 12 hours, and the other group received vancomycin 1 g every 12 hours intravenously. Both groups received concomitant aztreonam (1 to 2 g every 8 hours intravenously), which could be continued if clinically indicated. There were 203 linezolid-treated and 193 vancomycin-treated patients enrolled in the study. One hundred twenty-two (60%) linezolid-treated patients and 103 (53%) vancomycin-treated patients were clinically evaluable. The cure rates in clinically evaluable patients were 57% for linezolid-treated patients and 60% for vancomycin-treated patients. The cure rates in clinically evaluable patients with ventilator-associated pneumonia were 47% for linezolid-treated patients and 40% for vancomycin-treated patients. A modified intent-to-treat (MITT) analysis of 94 linezolid-treated patients and 83 vancomycin-treated patients included subjects who had a pathogen isolated before treatment. The cure rates in the MITT analysis were 57% in linezolid-treated patients and 46% in vancomycin-treated patients. The cure rates by pathogen for microbiologically evaluable patients are presented in Table 8.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 8. Cure Rates at the Test-of-Cure Visit for Microbiologically Evaluable Adult Patients with Nosocomial Pneumonia</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Pathogen</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Cured</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ZYVOX</strong></p><p><strong>n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Vancomycin</strong></p><p><strong>n/N (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus</em></p></td><td style="vertical-align:top"><p>23/38 (61)</p></td><td style="vertical-align:top"><p>14/23 (61)</p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-resistant<em> S. aureus</em></p></td><td style="vertical-align:top"><p>13/22 (59)</p></td><td style="vertical-align:top"><p>7/10 (70)</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumonia</em></p></td><td style="vertical-align:top"><p>9/9 (100)</p></td><td style="vertical-align:top"><p>9/10 (90)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><u>Complicated Skin and Skin Structure Infections</u></p><p>Adult patients with clinically documented complicated skin and skin structure infections were enrolled in a randomized, multi-center, double-blind, double-dummy trial comparing study medications administered intravenously followed by medications given orally for a total of 10 to 21 days of treatment. One group of patients received ZYVOX I.V. Injection 600 mg every 12 hours followed by ZYVOX Tablets 600 mg every 12 hours; the other group received oxacillin 2 g every 6 hours intravenously followed by dicloxacillin 500 mg every 6 hours orally. Patients could receive concomitant aztreonam if clinically indicated. There were 400 linezolid-treated and 419 oxacillin-treated patients enrolled in the study. Two hundred forty-five (61%) linezolid-treated patients and 242 (58%) oxacillin-treated patients were clinically evaluable. The cure rates in clinically evaluable patients were 90% in linezolid-treated patients and 85% in oxacillin-treated patients. A modified intent-to-treat (MITT) analysis of 316 linezolid-treated patients and 313 oxacillin-treated patients included subjects who met all criteria for study entry. The cure rates in the MITT analysis were 86% in linezolid-treated patients and 82% in oxacillin-treated patients. The cure rates by pathogen for microbiologically evaluable patients are presented in Table 9.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 9. Cure Rates at the Test-of-Cure Visit for Microbiologically Evaluable Adult Patients with</strong> <strong>Complicated Skin and Skin Structure Infections</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Pathogen</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Cured</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ZYVOX</strong></p><p><strong>n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Oxacillin/Dicloxacillin</strong></p><p><strong>n/N (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus</em></p></td><td style="vertical-align:top"><p>73/83 (88)</p></td><td style="vertical-align:top"><p>72/84 (86)</p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-resistant <em>S. aureus</em></p></td><td style="vertical-align:top"><p>2/3 (67)</p></td><td style="vertical-align:top"><p>0/0 (-)</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus agalactiae</em></p></td><td style="vertical-align:top"><p>6/6 (100)</p></td><td style="vertical-align:top"><p>3/6 (50)</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pyogenes</em></p></td><td style="vertical-align:top"><p>18/26 (69)</p></td><td style="vertical-align:top"><p>21/28 (75)</p></td></tr></tbody></table><p>A separate study provided additional experience with the use of ZYVOX in the treatment of methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) infections. This was a randomized, open-label trial in hospitalized adult patients with documented or suspected MRSA infection.</p><p>One group of patients received ZYVOX I.V. Injection 600 mg every 12 hours followed by ZYVOX Tablets 600 mg every 12 hours. The other group of patients received vancomycin 1 g every 12 hours intravenously. Both groups were treated for 7 to 28 days, and could receive concomitant aztreonam or gentamicin if clinically indicated. The cure rates in microbiologically evaluable patients with MRSA skin and skin structure infection were 26/33 (79%) for linezolid-treated patients and 24/33 (73%) for vancomycin-treated patients.</p><p><u>Diabetic Foot Infections</u></p><p>Adult diabetic patients with clinically documented complicated skin and skin structure infections (&ldquo;diabetic foot infections&rdquo;) were enrolled in a randomized (2:1 ratio), multi-center, open-label trial comparing study medications administered intravenously or orally for a total of 14 to 28 days of treatment. One group of patients received ZYVOX 600 mg every 12 hours intravenously or orally; the other group received ampicillin/sulbactam 1.5 to 3 g intravenously or amoxicillin/clavulanate 500 to 875 mg every 8 to 12 hours orally. In countries where ampicillin/sulbactam is not marketed, amoxicillin/clavulanate 500 mg to 2 g every 6 hours was used for the intravenous regimen. Patients in the comparator group could also be treated with vancomycin 1 g every 12 hours intravenously if MRSA was isolated from the foot infection. Patients in either treatment group who had Gram-negative bacilli isolated from the infection site could also receive aztreonam 1 to 2 g every 8-12 hours intravenously. All patients were eligible to receive appropriate adjunctive treatment methods, such as debridement and off-loading, as typically required in the treatment of diabetic foot infections, and most patients received these treatments. There were 241 linezolid-treated and 120 comparator-treated patients in the intent-to-treat (ITT) study population. Two hundred twelve (86%) linezolid-treated patients and 105 (85%) comparator-treated patients were clinically evaluable. In the ITT population, the cure rates were 68.5% (165/241) in linezolid-treated patients and 64% (77/120) in comparator-treated patients, where those with indeterminate and missing outcomes were considered failures. The cure rates in the clinically evaluable patients (excluding those with indeterminate and missing outcomes) were 83% (159/192) and 73% (74/101) in the linezolid- and comparator-treated patients, respectively. A critical post-hoc analysis focused on 121 linezolid-treated and 60 comparator-treated patients who had a Gram-positive pathogen isolated from the site of infection or from blood, who had less evidence of underlying osteomyelitis than the overall study population, and who did not receive prohibited antimicrobials. Based upon that analysis, the cure rates were 71% (86/121) in the linezolid-treated patients and 63% (38/60) in the comparator-treated patients. None of the above analyses were adjusted for the use of adjunctive therapies. The cure rates by pathogen for microbiologically evaluable patients are presented in Table 10.</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 10. Cure Rates at the Test-of-Cure Visit for Microbiologically</strong></p><p><strong>Evaluable Adult Patients with</strong> <strong>Diabetic Foot Infections</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Pathogen</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Cured</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ZYVOX</strong></p><p><strong>n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Comparator</strong></p><p><strong>n/N (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus</em></p></td><td style="vertical-align:top"><p>49/63 (78)</p></td><td style="vertical-align:top"><p>20/29 (69)</p></td></tr><tr><td style="vertical-align:top"><p>Methicillin-resistant <em>S. aureus</em></p></td><td style="vertical-align:top"><p>12/17 (71)</p></td><td style="vertical-align:top"><p>2/3 (67)</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus agalactiae</em></p></td><td style="vertical-align:top"><p>25/29 (86)</p></td><td style="vertical-align:top"><p>9/16 (56)</p></td></tr></tbody></table><p><u>Vancomycin-Resistant Enterococcal Infections</u></p><p>Adult patients with documented or suspected vancomycin-resistant enterococcal infection were enrolled in a randomized, multi-center, double-blind trial comparing a high dose of ZYVOX (600 mg) with a low dose of ZYVOX (200 mg) given every 12 hours either intravenously (IV) or orally for 7 to 28 days. Patients could receive concomitant aztreonam or aminoglycosides. There were 79 patients randomized to high-dose linezolid and 66 to low-dose linezolid. The intent-to-treat (ITT) population with documented vancomycin-resistant enterococcal infection at baseline consisted of 65 patients in the high-dose arm and 52 in the low-dose arm.</p><p>The cure rates for the ITT population with documented vancomycin-resistant enterococcal infection at baseline are presented in Table 11 by source of infection. These cure rates do not include patients with missing or indeterminate outcomes. The cure rate was higher in the high-dose arm than in the low-dose arm, although the difference was not statistically significant at the 0.05 level.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 11. Cure Rates at the Test-of-Cure Visit for ITT Adult Patients with Documented Vancomycin-Resistant Enterococcal Infections at Baseline</strong></p></td></tr><tr><td rowspan="2"><p><strong>Source of Infection</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Cured</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ZYVOX</strong></p><p><strong>600 mg every 12 hours</strong></p><p><strong>n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>ZYVOX</strong></p><p><strong>200 mg every 12 hours</strong></p><p><strong>n/N (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Any site</p></td><td style="vertical-align:top"><p>39/58 (67)</p></td><td style="vertical-align:top"><p>24/46 (52)</p></td></tr><tr><td style="vertical-align:top"><p>Any site with associated bacteremia</p></td><td style="vertical-align:top"><p>10/17 (59)</p></td><td style="vertical-align:top"><p>4/14 (29)</p></td></tr><tr><td style="vertical-align:top"><p>Bacteremia of unknown origin</p></td><td style="vertical-align:top"><p>5/10 (50)</p></td><td style="vertical-align:top"><p>2/7 (29)</p></td></tr><tr><td style="vertical-align:top"><p>Skin and skin structure</p></td><td style="vertical-align:top"><p>9/13 (69)</p></td><td style="vertical-align:top"><p>5/5 (100)</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract</p></td><td style="vertical-align:top"><p>12/19 (63)</p></td><td style="vertical-align:top"><p>12/20 (60)</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia</p></td><td style="vertical-align:top"><p>2/3 (67)</p></td><td style="vertical-align:top"><p>0/1 (0)</p></td></tr><tr><td style="vertical-align:top"><p>Other<sup>*</sup></p></td><td style="vertical-align:top"><p>11/13 (85)</p></td><td style="vertical-align:top"><p>5/13 (39)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>Includes sources of infection such as hepatic abscess, biliary sepsis, necrotic gall bladder, pericolonic abscess, pancreatitis, and catheter-related infection.</p></td></tr></tbody></table><p><strong>Pediatric Patients</strong></p><p><u>Infections due to Gram-positive Bacteria</u></p><p>A safety and efficacy study provided experience on the use of ZYVOX in pediatric patients for the treatment of nosocomial pneumonia, complicated skin and skin structure infections, and other infections due to Gram-positive bacterial pathogens, including methicillin-resistant and -susceptible <em>Staphylococcus aureus</em> and vancomycin-resistant <em>Enterococcus faecium</em>.<strong> </strong>Pediatric patients ranging in age from birth through 11 years with infections caused by the documented or suspected Gram-positive bacteria were enrolled in a randomized, open-label, comparator-controlled trial. One group of patients received ZYVOX I.V. Injection 10 mg/kg every 8 hours followed by ZYVOX for Oral Suspension 10&nbsp;mg/kg every 8 hours. A second group received vancomycin 10 to 15 mg/kg intravenously every 6 to 24 hours, depending on age and renal clearance. Patients who had confirmed VRE infections were placed in a third arm of the study and received ZYVOX 10 mg/kg every 8 hours intravenously and/or orally. All patients were treated for a total of 10 to 28 days and could receive concomitant Gram-negative antibacterial drugs if clinically indicated. In the intent-to-treat (ITT) population, there were 206 patients randomized to linezolid and 102 patients randomized to vancomycin. The cure rates for ITT, MITT, and clinically evaluable patients are presented in Table 12. After the study was completed, 13 additional patients ranging from 4 days through 16 years of age were enrolled in an open-label extension of the VRE arm of the study. Table 13 provides clinical cure rates by pathogen for microbiologically evaluable patients including microbiologically evaluable patients with vancomycin-resistant <em>Enterococcus faecium </em>from the extension of this study.</p><table border="1" cellspacing="0" cellpadding="0" style="width:640px"><tbody><tr><td colspan="10" style="vertical-align:top"><p><strong>Table 12. Cure Rates at the Test-of-Cure Visit for Intent-to-Treat, Modified Intent-to-Treat, and Clinically Evaluable Pediatric Patients for the Overall Population and by Select Baseline Diagnosis</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Population</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>ITT</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>MITT<sup>*</sup></strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Clinically Evaluable</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ZYVOX</strong></p><p><strong>n/N (%)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Vancomycin</strong></p><p><strong>n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>ZYVOX</strong></p><p><strong>n/N (%)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Vancomycin</strong></p><p><strong>n/N (%)</strong></p></td><td style="vertical-align:top"><p><strong>ZYVOX</strong></p><p><strong>n/N (%)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Vancomycin</strong></p><p><strong>n/N (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Any diagnosis</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>150/186 (81)</p></td><td colspan="2" style="vertical-align:top"><p>69/83 (83)</p></td><td style="vertical-align:top"><p>86/108 (80)</p></td><td colspan="2" style="vertical-align:top"><p>44/49 (90)</p></td><td style="vertical-align:top"><p>106/117 (91)</p></td><td colspan="2" style="vertical-align:top"><p>49/54 (91)</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and skin structure infections</p></td><td style="vertical-align:top"><p>61/72 (85)</p></td><td colspan="2" style="vertical-align:top"><p>31/34 (91)</p></td><td style="vertical-align:top"><p>37/43 (86)</p></td><td colspan="2" style="vertical-align:top"><p>22/23 (96)</p></td><td style="vertical-align:top"><p>46/49 (94)</p></td><td colspan="2" style="vertical-align:top"><p>26/27 (96)</p></td></tr><tr><td style="vertical-align:top"><p>Nosocomial pneumonia</p></td><td style="vertical-align:top"><p>13/18 (72)</p></td><td colspan="2" style="vertical-align:top"><p>11/12 (92)</p></td><td style="vertical-align:top"><p>5/6 (83)</p></td><td colspan="2" style="vertical-align:top"><p>4/4 (100)</p></td><td style="vertical-align:top"><p>7/7 (100)</p></td><td colspan="2" style="vertical-align:top"><p>5/5 (100)</p></td></tr><tr><td colspan="10" style="vertical-align:top"><p><sup>*</sup>MITT = ITT patients with<sup> </sup>an isolated Gram-positive pathogen at baseline</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p><strong>Table 13. Cure Rates at the Test-of-Cure Visit for Microbiologically Evaluable Pediatric Patients with Infections due to Gram-positive Pathogens</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Pathogen</strong></p></td><td colspan="6" style="vertical-align:top"><p><strong>Microbiologically Evaluable</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ZYVOX</strong></p><p><strong>n/N (%)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Vancomycin</strong></p><p><strong>n/N (%)</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Vancomycin-resistant <em>Enterococcus faecium</em></p></td><td colspan="3" style="vertical-align:top"><p>6/8 (75)*</p></td><td colspan="3" style="vertical-align:top"><p>0/0 (-)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Staphylococcus aureus</em></p></td><td colspan="3" style="vertical-align:top"><p>36/38 (95)</p></td><td colspan="3" style="vertical-align:top"><p>23/24 (96)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Methicillin-resistant <em>S. aureus</em></p></td><td colspan="3" style="vertical-align:top"><p>16/17 (94)</p></td><td colspan="3" style="vertical-align:top"><p>9/9 (100)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><em>Streptococcus pyogenes</em></p></td><td colspan="3" style="vertical-align:top"><p>2/2 (100)</p></td><td colspan="3" style="vertical-align:top"><p>1/2 (50)</p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong><sup>*</sup></strong><strong> </strong>Includes data from 7 patients enrolled in the open-label extension of this study</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The mean pharmacokinetic parameters of linezolid in adults after single and multiple oral and intravenous doses are summarized in Table 14. Plasma concentrations of linezolid at steady-state after oral doses of 600 mg given every 12 hours are shown in Figure 1.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="8" style="vertical-align:top"><p><strong>Table 14.&nbsp; Mean (Standard Deviation) Pharmacokinetic Parameters of Linezolid in Adults</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Dose of Linezolid</strong></p></td><td style="vertical-align:top"><p><strong>C<sub>max</sub></strong></p><p><strong>mcg/mL</strong></p></td><td style="vertical-align:top"><p><strong>C<sub>min</sub></strong></p><p><strong>mcg/mL</strong></p></td><td style="vertical-align:top"><p><strong>T<sub>max</sub></strong></p><p><strong>hrs</strong></p></td><td style="vertical-align:top"><p><strong>AUC <sup>*</sup></strong></p><p><strong>mcg&bull;h/mL</strong></p></td><td style="vertical-align:top"><p><strong>t<sub>1/2</sub></strong></p><p><strong>hrs</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>CL</strong></p><p><strong>mL/min</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>400 mg tablet </strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; single dose <sup>&dagger;</sup></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; every 12 hours</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>8.10</p><p>(1.83)</p><p>&nbsp;</p><p>11.00</p><p>(4.37)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>---</p><p>&nbsp;</p><p>&nbsp;</p><p>3.08</p><p>(2.25)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.52</p><p>(1.01)</p><p>&nbsp;</p><p>1.12</p><p>(0.47)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>55.10</p><p>(25.00)</p><p>&nbsp;</p><p>73.40</p><p>(33.50)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>5.20</p><p>(1.50)</p><p>&nbsp;</p><p>4.69</p><p>(1.70)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>146</p><p>(67)</p><p>&nbsp;</p><p>110</p><p>(49)</p></td></tr><tr><td style="vertical-align:top"><p><strong>600 mg tablet</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; single dose</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; every 12 hours</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>12.70</p><p>(3.96)</p><p>&nbsp;</p><p>21.20</p><p>(5.78)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>---</p><p>&nbsp;</p><p>&nbsp;</p><p>6.15</p><p>(2.94)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.28</p><p>(0.66)</p><p>&nbsp;</p><p>1.03</p><p>(0.62)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>91.40</p><p>(39.30)</p><p>&nbsp;</p><p>138.00</p><p>(42.10)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4.26</p><p>(1.65)</p><p>&nbsp;</p><p>5.40</p><p>(2.06)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>127</p><p>(48)</p><p>&nbsp;</p><p>80</p><p>(29)</p></td></tr><tr><td style="vertical-align:top"><p><strong>600 mg IV injection </strong><sup>&Dagger;</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; single dose</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; every 12 hours</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>12.90</p><p>(1.60)</p><p>&nbsp;</p><p>15.10</p><p>(2.52)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>---</p><p>&nbsp;</p><p>&nbsp;</p><p>3.68</p><p>(2.36)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.50</p><p>(0.10)</p><p>&nbsp;</p><p>0.51</p><p>(0.03)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>80.20</p><p>(33.30)</p><p>&nbsp;</p><p>89.70</p><p>(31.00)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4.40</p><p>(2.40)</p><p>&nbsp;</p><p>4.80</p><p>(1.70)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>138</p><p>(39)</p><p>&nbsp;</p><p>123</p><p>(40)</p></td></tr><tr><td style="vertical-align:top"><p><strong>600 mg oral suspension</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; single dose</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>11.00</p><p>(2.76)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>---</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0.97</p><p>(0.88)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>80.80</p><p>(35.10)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>4.60</p><p>(1.71)</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p>141</p><p>(45)</p><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp; AUC for single dose = AUC<sub>0-&infin;</sub>; for multiple dose = AUC<sub>0-&tau;</sub></p><p><sup>&dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp; Data dose-normalized from 375 mg</p><p><sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;&nbsp; Data dose-normalized from 625 mg, intravenous dose was given as 0.5-hour infusion. C<sub>max</sub> = Maximum plasma concentration; C<sub>min</sub> = Minimum plasma concentration; T<sub>max</sub> = Time to C<sub>max</sub>; AUC = Area under concentration-time curve; t<sub>1/2</sub> = Elimination half-life; CL = Systemic clearance</p><p><strong><em>&nbsp;</em></strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:420.6pt;
 height:182.4pt' fillcolor="window">
 <v:imagedata src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="561" height="243" src="file:///C:/Users/ibrahw02/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg" /></p><p><strong>Figure 1. Plasma Concentrations of Linezolid in Adults at Steady-State Following Oral Dosing Every 12 Hours (Mean </strong><strong>&plusmn;</strong><strong> Standard Deviation, n=16)</strong></p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Absorption</u></p><p>Linezolid is extensively absorbed after oral dosing. Maximum plasma concentrations are reached approximately 1 to 2&nbsp;hours after dosing, and the absolute bioavailability is approximately 100%. Therefore, linezolid may be given orally or intravenously without dose adjustment.</p><p>Linezolid may be administered without regard to the timing of meals. The time to reach the maximum concentration is delayed from 1.5 hours to 2.2 hours and C<sub>max</sub> is decreased by about 17% when high fat food is given with linezolid. However, the total exposure measured as AUC<sub>0‑</sub><sub>&yen;</sub> is similar under both conditions.</p><p><u>Distribution</u></p><p>Animal and human pharmacokinetic studies have demonstrated that linezolid readily distributes to well-perfused tissues. The plasma protein binding of linezolid is approximately 31% and is concentration-independent. The volume of distribution of linezolid at steady-state averaged 40 to 50 liters in healthy adult volunteers.</p><p>Linezolid concentrations have been determined in various fluids from a limited number of subjects in Phase 1 volunteer studies following multiple dosing of linezolid. The ratio of linezolid in saliva relative to plasma was 1.2 to 1 and the ratio of linezolid in sweat relative to plasma was 0.55&nbsp;to&nbsp;1.</p><p><u>Metabolism</u></p><p>Linezolid is primarily metabolized by oxidation of the morpholine ring, which results in two inactive ring-opened carboxylic acid metabolites: the aminoethoxyacetic acid metabolite (A), and the hydroxyethyl glycine metabolite (B). Formation of metabolite A is presumed to be formed via an enzymatic pathway whereas metabolite B is mediated by a non-enzymatic chemical oxidation mechanism in vitro. In vitro studies have demonstrated that linezolid is minimally metabolized and may be mediated by human cytochrome P450. However, the metabolic pathway of linezolid is not fully understood.</p><p><u>Excretion</u></p><p>Nonrenal clearance accounts for approximately 65% of the total clearance of linezolid. Under steady-state conditions, approximately 30% of the dose appears in the urine as linezolid, 40% as metabolite B, and 10% as metabolite A. The mean renal clearance of linezolid is 40&nbsp;mL/min which suggests net tubular reabsorption. Virtually no linezolid appears in the feces, while approximately 6% of the dose appears in the feces as metabolite B, and 3% as metabolite A.</p><p>A small degree of nonlinearity in clearance was observed with increasing doses of linezolid, which appears to be due to lower renal and nonrenal clearance of linezolid at higher concentrations. However, the difference in clearance was small and was not reflected in the apparent elimination half-life.</p><p><u>Specific Populations</u></p><p><em>Geriatric Patients</em></p><p>The pharmacokinetics of linezolid are not significantly altered in elderly patients (65 years or older). Therefore, dose adjustment for geriatric patients is not necessary.</p><p><em>Pediatric Patients</em></p><p>The pharmacokinetics of linezolid following a single intravenous dose were investigated in pediatric patients ranging in age from birth through 17 years (including premature and full-term neonates), in healthy adolescent subjects ranging in age from 12 through 17 years, and in pediatric patients ranging in age from 1 week through 12 years. The pharmacokinetic parameters of linezolid are summarized in Table 15 for the pediatric populations studied and healthy adult subjects after administration of single intravenous doses.</p><p>The C<sub>max</sub> and the volume of distribution (V<sub>ss</sub>) of linezolid are similar regardless of age in pediatric patients. However, plasma clearance of linezolid varies as a function of age. With the exclusion of pre-term neonates less than one week of age, weight-based clearance is most rapid in the youngest age groups ranging from &lt; 1 week old to 11 years, resulting in lower single-dose systemic exposure (AUC) and a shorter half-life as compared with adults. As the age of pediatric patients increases, the weight-based clearance of linezolid gradually decreases, and by adolescence mean clearance values approach those observed for the adult population. There is increased inter-subject variability in linezolid clearance and systemic drug exposure (AUC) across all pediatric age groups as compared with adults.</p><p>Similar mean daily AUC values were observed in pediatric patients from birth to 11 years of age dosed every 8 hours relative to adolescents or adults dosed every 12 hours. Therefore, the dosage for pediatric patients up to 11 years of age should be 10 mg/kg every 8 hours. Pediatric patients 12 years and older should receive 600 mg every 12 hours [<em>see Posology and Methods of Administration (4.2)</em>].</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong>Table 15. Pharmacokinetic Parameters of Linezolid in Pediatrics and Adults Following a Single Intravenous Infusion of 10 mg/kg or 600 mg Linezolid (Mean: (%CV); [Min, Max Values])</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Age Group</strong></p></td><td style="vertical-align:top"><p><strong>C<sub>max</sub></strong></p><p><strong>mcg/mL</strong></p></td><td style="vertical-align:top"><p><strong>V<sub>ss</sub></strong></p><p><strong>L/kg</strong></p></td><td style="vertical-align:top"><p><strong>AUC<sup>*</sup></strong></p><p><strong>mcg</strong><strong>&middot;</strong><strong>h/mL</strong></p></td><td style="vertical-align:top"><p><strong>t <sub>1/2</sub></strong></p><p><strong>Hrs</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>CL</strong></p><p><strong>mL/min/kg</strong></p></td></tr><tr><td style="vertical-align:top"><p>Neonatal Patients</p><p>Pre-term<sup>** </sup></p><p>&lt; 1 week (N=9)<sup>&dagger;</sup></p></td><td><p>12.7 (30%)</p><p>[9.6, 22.2]</p></td><td><p>0.81 (24%)</p><p>[0.43, 1.05]</p></td><td><p>108 (47%)</p><p>[41, 191]</p></td><td><p>5.6 (46%)</p><p>[2.4, 9.8]</p></td><td colspan="2"><p>2.0 (52%)</p><p>[0.9, 4.0]</p></td></tr><tr><td style="vertical-align:top"><p>Full-term<sup>***</sup></p><p>&lt; 1 week (N=10)<sup>&dagger;</sup></p></td><td><p>11.5 (24%)</p><p>[8.0, 18.3]</p></td><td><p>0.78 (20%)</p><p>[0.45, 0.96]</p></td><td><p>55 (47%)</p><p>[19, 103]</p></td><td><p>3.0 (55%)</p><p>[1.3, 6.1]</p></td><td colspan="2"><p>3.8 (55%)</p><p>[1.5, 8.8]</p></td></tr><tr><td style="vertical-align:top"><p>Full-term<sup>***</sup></p><p>&sup3; 1 week to &le; 28 days (N=10)<sup>&dagger; </sup></p></td><td><p>12.9 (28%)</p><p>[7.7, 21.6]</p></td><td><p>0.66 (29%)</p><p>[0.35, 1.06]</p></td><td><p>34 (21%)</p><p>[23, 50]</p></td><td><p>1.5 (17%)</p><p>[1.2, 1.9]</p></td><td colspan="2"><p>5.1 (22%)</p><p>[3.3, 7.2]</p></td></tr><tr><td style="vertical-align:top"><p>Infant Patients</p><p>&gt; 28 days to &lt; 3 Months (N=12)<sup>&dagger;</sup></p></td><td><p>11.0 (27%)</p><p>[7.2, 18.0]</p></td><td><p>0.79 (26%)</p><p>[0.42, 1.08]</p></td><td><p>33 (26%)</p><p>[17, 48]</p></td><td><p>1.8 (28%)</p><p>[1.2, 2.8]</p></td><td colspan="2"><p>5.4 (32%)</p><p>[3.5, 9.9]</p></td></tr><tr><td style="vertical-align:top"><p>Pediatric Patients</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3 months through 11&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; years<sup>&dagger;</sup> (N=59)</p></td><td><p>15.1 (30%)</p><p>[6.8, 36.7]</p></td><td><p>0.69 (28%)</p><p>[0.31, 1.50]</p></td><td><p>58 (54%)</p><p>[19, 153]</p></td><td><p>2.9 (53%)</p><p>[0.9, 8.0]</p></td><td colspan="2"><p>3.8 (53%)</p><p>[1.0, 8.5]</p></td></tr><tr><td style="vertical-align:top"><p>Adolescent Subjects and Patients&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12 through 17 years<sup>&Dagger;</sup>&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (N=36)</p></td><td><p>16.7 (24%)</p><p>[9.9, 28.9]</p></td><td><p>0.61 (15%)</p><p>[0.44, 0.79]</p></td><td><p>95 (44%)</p><p>[32, 178]</p></td><td><p>4.1 (46%)</p><p>[1.3, 8.1]</p></td><td colspan="2"><p>2.1 (53%)</p><p>[0.9, 5.2]</p></td></tr><tr><td style="vertical-align:bottom"><p>Adult Subjects<sup>&sect;</sup></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (N= 29)</p></td><td><p>12.5 (21%)</p><p>[8.2, 19.3]</p></td><td><p>0.65 (16%)</p><p>[0.45, 0.84]</p></td><td><p>91 (33%)</p><p>[53, 155]</p></td><td><p>4.9 (35%)</p><p>[1.8, 8.3]</p></td><td colspan="2"><p>1.7 (34%)</p><p>[0.9, 3.3]</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>*</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AUC = Single dose AUC<sub>0-</sub><sub>&yen;</sub></p><p><sup>**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>In this data set, &ldquo;pre-term&rdquo; is defined as &lt;34 weeks gestational age (Note: Only 1 patient enrolled was pre-term with a postnatal age between 1 week and 28 days)</p><p><sup>***&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>In this data set, &ldquo;full-term&rdquo; is defined as &sup3;34 weeks gestational age</p><p><sup>&dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Dose of 10 mg/kg</p><p><sup>&Dagger;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Dose of 600 mg or 10 mg/kg up to a maximum of 600 mg</p><p><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose normalized to 600 mg</p><p>C<sub>max</sub> = Maximum plasma concentration; V<sub>ss=</sub> Volume of distribution; AUC = Area under concentration-time curve;</p><p>t<sub>1/2</sub> = Apparent elimination half-life; CL = Systemic clearance normalized for body weight</p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><em>Gender</em></p><p>Females have a slightly lower volume of distribution of linezolid than males. Plasma concentrations are higher in females than in males, which is partly due to body weight differences. After a 600-mg dose, mean oral clearance is approximately 38% lower in females than in males. However, there are no significant gender differences in mean apparent elimination-rate constant or half-life. Thus, drug exposure in females is not expected to substantially increase beyond levels known to be well tolerated. Therefore, dose adjustment by gender does not appear to be necessary.</p><p><em>Renal Impairment</em></p><p>The pharmacokinetics of the parent drug, linezolid, are not altered in patients with any degree of renal impairment; however, the two primary metabolites of linezolid accumulate in patients with renal impairment, with the amount of accumulation increasing with the severity of renal dysfunction (see Table 16). The pharmacokinetics of linezolid and its two metabolites have also been studied in patients with end-stage renal disease (ESRD) receiving hemodialysis. In the ESRD study, 14 patients were dosed with linezolid 600 mg every 12 hours for 14.5 days (see Table 17). Because similar plasma concentrations of linezolid are achieved regardless of renal function, no dose adjustment is recommended for patients with renal impairment. However, given the absence of information on the clinical significance of accumulation of the primary metabolites, use of linezolid in patients with renal impairment should be weighed against the potential risks of accumulation of these metabolites. Both linezolid and the two metabolites are eliminated by hemodialysis. No information is available on the effect of peritoneal dialysis on the pharmacokinetics of linezolid. Approximately 30% of a dose was eliminated in a 3-hour hemodialysis session beginning 3&nbsp;hours after the dose of linezolid was administered; therefore, linezolid should be given after hemodialysis.</p><p><strong>Table 16. Mean (Standard Deviation) AUCs and Elimination Half-lives of Linezolid and Metabolites A and B in Patients with Varying Degrees of Renal Impairment After a Single 600 mg Oral Dose of Linezolid</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:623px"><tbody><tr><td colspan="4" style="vertical-align:top">&nbsp;<p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p><strong>Healthy Subjects </strong><strong>CL<sub>CR</sub> </strong><strong>&gt;&nbsp;80 mL/min</strong></p></td><td style="vertical-align:top"><p><strong>Moderate Renal</strong></p><p><strong>Impairment 30 &lt;&nbsp;</strong><strong>CL<sub>CR</sub> </strong><strong><sub>&nbsp;</sub></strong></p><p><strong>&lt; 80 mL/min</strong></p></td><td style="vertical-align:top"><p><strong>Severe Renal</strong></p><p><strong>Impairment</strong> <strong>10&nbsp;&lt; </strong><strong>CL<sub>CR</sub> </strong></p><p><strong>&lt; 30 mL/min</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong><u>LINEZOLID</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-</sub><sub>&yen;</sub>, mcg&nbsp;h/mL</p></td><td style="vertical-align:top"><p>110 (22)</p></td><td style="vertical-align:top"><p>128 (53)</p></td><td style="vertical-align:top"><p>127 (66)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>1/2</sub>,<sub> </sub>hours</p></td><td style="vertical-align:top"><p>6.4 (2.2)</p></td><td style="vertical-align:top"><p>6.1 (1.7)</p></td><td style="vertical-align:top"><p>7.1 (3.7)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong><u>METABOLITE A</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-48</sub>, mcg h/mL</p></td><td style="vertical-align:top"><p>7.6 (1.9)</p></td><td style="vertical-align:top"><p>11.7 (4.3)</p></td><td style="vertical-align:top"><p>56.5 (30.6)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>1/2</sub>, hours</p></td><td style="vertical-align:top"><p>6.3 (2.1)</p></td><td style="vertical-align:top"><p>6.6 (2.3)</p></td><td style="vertical-align:top"><p>9.0 (4.6)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong><u>METABOLITE B</u></strong><strong><sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-48</sub>, mcg&nbsp;h/mL</p></td><td style="vertical-align:top"><p>30.5 (6.2)</p></td><td style="vertical-align:top"><p>51.1 (38.5)</p></td><td style="vertical-align:top"><p>203 (92)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>1/2</sub>, hours</p></td><td style="vertical-align:top"><p>6.6 (2.7)</p></td><td style="vertical-align:top"><p>9.9 (7.4)</p></td><td style="vertical-align:top"><p>11.0 (3.9)</p></td></tr></tbody></table><p><sup>1 </sup>Metabolite B is the major metabolite of linezolid.</p><table border="0" cellspacing="0" cellpadding="0" style="width:634px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 17. Mean (Standard Deviation) AUCs and Elimination Half-lives of Linezolid and Metabolites A and B in Subjects with End-Stage Renal Disease (ESRD) After the Administration of 600 mg Linezolid Every 12 Hours for 14.5 Days</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Parameter</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>ESRD Subjects</strong><strong><sup>1</sup></strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><u>LINEZOLID</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-12</sub>, mcg&nbsp;h/mL (after last dose)</p></td><td colspan="2" style="vertical-align:top"><p>181 (52.3)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>1/2</sub>, h (after last dose)</p></td><td colspan="2" style="vertical-align:top"><p>8.3 (2.4)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><u>METABOLITE A</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-12</sub>, mcg &nbsp;h/mL (after last dose)</p></td><td colspan="2" style="vertical-align:top"><p>153 (40.6)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>1/2</sub>, h (after last dose)</p></td><td colspan="2" style="vertical-align:top"><p>15.9 (8.5)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><u>METABOLITE B</u></strong><strong><sup>2</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-12</sub>, mcg&nbsp;h/mL (after last dose)</p></td><td colspan="2" style="vertical-align:top"><p>356 (99.7)</p></td></tr><tr><td style="vertical-align:top"><p>t<sub>1/2</sub>, h (after last dose)</p></td><td colspan="2" style="vertical-align:top"><p>34.8 (23.1)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>1 </sup>between hemodialysis sessions</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>2 </sup>Metabolite B is the major metabolite of linezolid.</p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><em>Hepatic Impairment</em></p><p>The pharmacokinetics of linezolid are not altered in patients (n=7) with mild-to-moderate hepatic impairment (Child-Pugh class A or B). On the basis of the available information, no dose adjustment is recommended for patients with mild-to-moderate hepatic impairment. The pharmacokinetics of linezolid in patients with severe hepatic impairment have not been evaluated.</p><p><strong><u>Drug Interactions</u></strong></p><p><strong><em>Drugs Metabolized by Cytochrome P450</em></strong></p><p>Linezolid is not an inducer of cytochrome P450 (CYP450) in rats. In addition, linezolid does not inhibit the activities of clinically significant human CYP isoforms (e.g., 1A2, 2C9, 2C19, 2D6, 2E1, 3A4). Therefore, linezolid is not expected to affect the pharmacokinetics of other drugs metabolized by these major enzymes. Concurrent administration of linezolid does not substantially alter the pharmacokinetic characteristics of (S)-warfarin, which is extensively metabolized by CYP2C9. Drugs such as warfarin and phenytoin, which are CYP2C9 substrates, may be given with linezolid without changes in dosage regimen.</p><p><strong><em>Antibacterial Drugs </em></strong><em>Aztreonam</em>: The pharmacokinetics of linezolid or aztreonam are not altered when administered together.</p><p><em>Gentamicin</em>: The pharmacokinetics of linezolid or gentamicin are not altered when administered together.</p><p><strong><em>Antioxidants</em></strong></p><p>The potential for drug-drug interactions with linezolid and the antioxidants Vitamin C and Vitamin E was studied in healthy volunteers. Subjects were administered a 600 mg oral dose of linezolid on Day 1, and another 600 mg dose of linezolid on Day 8. On Days 2-9, subjects were given either Vitamin C (1,000 mg/day) or Vitamin E (800 IU/ day). The AUC<sub>0-&infin;</sub> of linezolid increased 2.3% when co-administered with Vitamin C and 10.9% when co-administered with Vitamin E. No linezolid dose adjustment is recommended during co-administration with Vitamin C or Vitamin E.</p><p><strong><em>Strong CYP 3A4 Inducers</em></strong></p><p>Rifampin: The effect of rifampin on the pharmacokinetics of linezolid was evaluated in a study of 16 healthy adult males. Volunteers were administered oral linezolid 600 mg twice daily for 5 doses with and without rifampin 600 mg once daily for 8 days. Co-administration of rifampin with linezolid resulted in a 21% decrease in linezolid C<sub>max</sub> [90% CI, 15% - 27%] and a 32% decrease in linezolid AUC<sub>0-12</sub> [90% CI, 27% - 37%]. The clinical significance of this interaction is unknown. The mechanism of this interaction is not fully understood and may be related to the induction of hepatic enzymes. Other strong inducers of hepatic enzymes (e.g. carbamazepine, phenytoin, phenobarbital) could cause a similar or smaller decrease in linezolid exposure.</p><p><strong><em>Monoamine Oxidase Inhibition</em></strong></p><p>Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. Therefore, linezolid has the potential for interaction with adrenergic and serotonergic agents.</p><p><strong><em>Adrenergic Agents</em></strong></p><p>Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents. Commonly used drugs such as phenylpropanolamine and pseudoephedrine have been specifically studied. Initial doses of adrenergic agents, such as dopamine or epinephrine, should be reduced and titrated to achieve the desired response.</p><p>Tyramine: A significant pressor response has been observed in normal adult subjects receiving linezolid and tyramine doses of more than 100 mg. Therefore, patients receiving linezolid need to avoid consuming large amounts of foods or beverages with high tyramine content.</p><p>Pseudoephedrine HCl or phenylpropanolamine HCl: A reversible enhancement of the pressor response of either pseudoephedrine HCl (PSE) or phenylpropanolamine HCl (PPA) is observed when linezolid is administered to healthy normotensive subjects [<em>see Special Warnings and Precautions for use (4.4) and Interaction with other medicinal products and other forms of interactions (4.5)</em>]. A similar study has not been conducted in hypertensive patients. The interaction studies conducted in normotensive subjects evaluated the blood pressure and heart rate effects of placebo, PPA or PSE alone, linezolid alone, and the combination of steady-state linezolid (600&nbsp;mg every 12 hours for 3 days) with two doses of PPA (25&nbsp;mg) or PSE (60 mg) given 4&nbsp;hours apart. Heart rate was not affected by any of the treatments. Blood pressure was increased with both combination treatments. Maximum blood pressure levels were seen 2 to 3&nbsp;hours after the second dose of PPA or PSE, and returned to baseline 2 to 3&nbsp;hours after peak. The results of the PPA study follow, showing the mean (and range) maximum systolic blood pressure in mm Hg: placebo&nbsp;=&nbsp;121 (103 to 158); linezolid alone&nbsp;=&nbsp;120 (107 to 135); PPA alone&nbsp;=&nbsp;125 (106 to 139); PPA with linezolid&nbsp;=&nbsp;147 (129 to 176). The results from the PSE study were similar to those in the PPA study. The mean maximum increase in systolic blood pressure over baseline was 32 mm Hg (range: 20-52 mm Hg) and 38 mm Hg (range: 18-79 mm Hg) during co-administration of linezolid with pseudoephedrine or phenylpropanolamine, respectively.</p><p><strong><em>Serotonergic Agents </em></strong></p><p>Dextromethorphan: The potential drug-drug interaction with dextromethorphan was studied in healthy volunteers. Subjects were administered dextromethorphan (two 20-mg doses given 4 hours apart) with or without linezolid. No serotonin syndrome effects (confusion, delirium, restlessness, tremors, blushing, diaphoresis, hyperpyrexia) have been observed in normal subjects receiving linezolid and dextromethorphan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility</strong></p><p>Lifetime studies in animals have not been conducted to evaluate the carcinogenic potential of linezolid. Neither mutagenic nor clastogenic potential was found in a battery of tests including: assays for mutagenicity (Ames bacterial reversion and CHO cell mutation), an in<em> </em>vitro unscheduled DNA synthesis (UDS) assay, an in vitro chromosome aberration assay in human lymphocytes, and an in vivo mouse micronucleus assay.</p><p>Linezolid did not affect the fertility or reproductive performance of adult female rats given oral doses of up to 100 mg/Kg/day for 14 days prior to mating through Gestation Day 7. It reversibly decreased fertility and reproductive performance in adult male rats when given at doses &sup3; 50&nbsp;mg/kg/day, with exposures approximately equal to or greater than the expected human exposure level (exposure comparisons are based on AUCs). The reversible fertility effects were mediated through altered spermatogenesis. Affected spermatids contained abnormally formed and oriented mitochondria and were non-viable. Epithelial cell hypertrophy and hyperplasia in the epididymis was observed in conjunction with decreased fertility. Similar epididymal changes were not seen in dogs.</p><p>In sexually mature male rats exposed to drug as juveniles, mildly decreased fertility was observed following treatment with linezolid through most of their period of sexual development (50 mg/kg/day from days 7 to 36 of age, and 100 mg/kg/day from days 37 to 55 of age), with exposures up to 1.7 times greater than mean AUCs observed in pediatric patients aged 3 months to 11 years. Decreased fertility was not observed with shorter treatment periods, corresponding to exposure in utero through the early neonatal period (gestation day 6 through postnatal day 5), neonatal exposure (postnatal days 5 to 21), or to juvenile exposure (postnatal days 22 to 35). Reversible reductions in sperm motility and altered sperm morphology were observed in rats treated from postnatal day 22 to 35.</p><p><strong>Animal Toxicology and/or Pharmacology</strong></p><p>Target organs of linezolid toxicity were similar in juvenile and adult rats and dogs. Dose- and time-dependent myelosuppression, as evidenced by bone marrow hypocellularity/decreased hematopoiesis, decreased extramedullary hematopoiesis in spleen and liver, and decreased levels of circulating erythrocytes, leukocytes, and platelets have been seen in animal studies. Lymphoid depletion occurred in thymus, lymph nodes, and spleen. Generally, the lymphoid findings were associated with anorexia, weight loss, and suppression of body weight gain, which may have contributed to the observed effects.</p><p>In rats administered linezolid orally for 6 months, non-reversible, minimal to mild axonal degeneration of sciatic nerves was observed at 80 mg/kg/day; minimal degeneration of the sciatic nerve was also observed in 1 male at this dose level at a 3-month interim necropsy. Sensitive morphologic evaluation of perfusion-fixed tissues was conducted to investigate evidence of optic nerve degeneration. Minimal to moderate optic nerve degeneration was evident in 2 male rats after 6 months of dosing, but the direct relationship to drug was equivocal because of the acute nature of the finding and its asymmetrical distribution. The nerve degeneration observed was microscopically comparable to spontaneous unilateral optic nerve degeneration reported in aging rats and may be an exacerbation of common background change.</p><p>These effects were observed at exposure levels that are comparable to those observed in some human subjects. The hematopoietic and lymphoid effects were reversible, although in some studies, reversal was incomplete within the duration of the recovery period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium citrate Dihydrate (1.64 mg/ml), Citric acid Anhydrous (0.85mg/ml), and Dextrose Monohydrate (50.24 mg/ml), and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Physical incompatibilities resulted when ZYVOX I.V. Injection was combined with the following drugs during simulated Y-site administration: amphotericin B, chlorpromazine HCl, diazepam, pentamidine isothionate, erythromycin lactobionate, phenytoin sodium, and trimethoprim-sulfamethoxazole. Additionally, chemical incompatibility resulted when ZYVOX I.V. Injection was combined with ceftriaxone sodium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Zyvox IV after the expiry date which is stated on the carton, bag and/ or overwrap after EXP: The expiry date refers to the last day of that month.

Shelf life: 36 months.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not store above 25&ordm;C (77&ordm;F). Protect from light. It is recommended that the infusion bags be kept in the overwrap until ready to use. Protect infusion bags from freezing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ZYVOX I.V. Injection is available in single-use, ready-to-use flexible plastic infusion bags in a foil laminate overwrap. The infusion bags and ports are latex-free. The infusion bags are available in the following package size: 10 bags * 300 ml.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zyvox solution for infusion is compatible with the following solutions: 5% glucose intravenous infusion, 0.9% sodium chloride intravenous infusion, Ringer-lactate solution for injection.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER
Pfizer Inc, New York, Unites States.

MANUFACTURED BY
HP Halden Pharma AS, Halden, Norway

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>